US7902200B2 - Chemical compounds - Google Patents
Chemical compounds Download PDFInfo
- Publication number
- US7902200B2 US7902200B2 US11/876,370 US87637007A US7902200B2 US 7902200 B2 US7902200 B2 US 7902200B2 US 87637007 A US87637007 A US 87637007A US 7902200 B2 US7902200 B2 US 7902200B2
- Authority
- US
- United States
- Prior art keywords
- oxy
- alkyl
- methyl
- ring
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 0 [1*]N1CCC(OC2=CC(C(=O)NC)=CC(OC)=C2)C1=O Chemical compound [1*]N1CCC(OC2=CC(C(=O)NC)=CC(OC)=C2)C1=O 0.000 description 38
- ADTBAOMAILMDJS-UHFFFAOYSA-N *.CCOC(=O)C(CCOS(C)(=O)=O)OC1=CC(OC)=CC(C(=O)NC)=C1 Chemical compound *.CCOC(=O)C(CCOS(C)(=O)=O)OC1=CC(OC)=CC(C(=O)NC)=C1 ADTBAOMAILMDJS-UHFFFAOYSA-N 0.000 description 2
- UNZQWJWYQIUWEM-JOCHJYFZSA-N CC1=CN=C(NC(=O)C2=CC(O[C@@H]3CCN(C)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@@H]3CCN(C)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 UNZQWJWYQIUWEM-JOCHJYFZSA-N 0.000 description 2
- LDJNSXYZAUMGLU-AWEZNQCLSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(O)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(O)=C2)C=N1 LDJNSXYZAUMGLU-AWEZNQCLSA-N 0.000 description 2
- UBMWBGWAHIJKOC-QHCPKHFHSA-N CCN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=CC(C(=O)NC3=NC=C(C)N=C3)=C2)C1=O Chemical compound CCN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=CC(C(=O)NC3=NC=C(C)N=C3)=C2)C1=O UBMWBGWAHIJKOC-QHCPKHFHSA-N 0.000 description 2
- IRSDODPFHFSXEU-KRWDZBQOSA-N CN1CC[C@H](OC2=CC(OC3=CC=C4C(=C3)OCCCS4(=O)=O)=CC(C(=O)O)=C2)C1=O Chemical compound CN1CC[C@H](OC2=CC(OC3=CC=C4C(=C3)OCCCS4(=O)=O)=CC(C(=O)O)=C2)C1=O IRSDODPFHFSXEU-KRWDZBQOSA-N 0.000 description 2
- DYNCMZCMVCMYSE-UHFFFAOYSA-N CC(C)N1C2CCC1CC2 Chemical compound CC(C)N1C2CCC1CC2 DYNCMZCMVCMYSE-UHFFFAOYSA-N 0.000 description 1
- FURXRIUSNLWPAX-UHFFFAOYSA-N CC(C)N1CC2CC1C2 Chemical compound CC(C)N1CC2CC1C2 FURXRIUSNLWPAX-UHFFFAOYSA-N 0.000 description 1
- ZKXOAHNMGYJRPS-UHFFFAOYSA-N CC1=C(C(C)C)C=C2OCCCCC2=C1 Chemical compound CC1=C(C(C)C)C=C2OCCCCC2=C1 ZKXOAHNMGYJRPS-UHFFFAOYSA-N 0.000 description 1
- SJFRCUMZSJTAEO-UHFFFAOYSA-N CC1=C/C2=CC=CC=C2/C=N\1.CC1=CC2=C(C=N1)C(=O)N(C)CC2.CC1=CC2=C(C=N1)C(=O)N(C)CCO2.CC1=CC2=C(C=N1)S(=O)(=O)CCC2.CC1=CC2=C(C=N1)S(=O)(=O)CCCO2.CC1=CC2=C(C=N1)S(=O)(=O)CCO2.CC1=CC2=C(N=C1)C(=O)N(C)CC2.CC1=CC2=C(N=C1)C(=O)N(C)CCO2.CC1=CC2=C(N=C1)N(C)C=C2.CC1=CC2=C(N=C1)NC=C2.CC1=CC2=C(N=C1)S(=O)(=O)CCC2.CC1=CC2=C(N=C1)S(=O)(=O)CCCO2.CC1=CC2=C(N=C1)S(=O)(=O)CCO2.CC1=NC2=C(C=C1)C(=O)N(C)CC2.CC1=NC2=C(C=C1)C(=O)N(C)CCO2.CC1=NC2=C(C=C1)S(=O)(=O)CCC2.CC1=NC2=C(C=C1)S(=O)(=O)CCCO2.CC1=NC2=C(C=C1)S(=O)(=O)CCO2.CC1=NC2=C(C=CC=C2)S1.CC1=NC2=C(N=C1)C(=O)N(C)CC2 Chemical compound CC1=C/C2=CC=CC=C2/C=N\1.CC1=CC2=C(C=N1)C(=O)N(C)CC2.CC1=CC2=C(C=N1)C(=O)N(C)CCO2.CC1=CC2=C(C=N1)S(=O)(=O)CCC2.CC1=CC2=C(C=N1)S(=O)(=O)CCCO2.CC1=CC2=C(C=N1)S(=O)(=O)CCO2.CC1=CC2=C(N=C1)C(=O)N(C)CC2.CC1=CC2=C(N=C1)C(=O)N(C)CCO2.CC1=CC2=C(N=C1)N(C)C=C2.CC1=CC2=C(N=C1)NC=C2.CC1=CC2=C(N=C1)S(=O)(=O)CCC2.CC1=CC2=C(N=C1)S(=O)(=O)CCCO2.CC1=CC2=C(N=C1)S(=O)(=O)CCO2.CC1=NC2=C(C=C1)C(=O)N(C)CC2.CC1=NC2=C(C=C1)C(=O)N(C)CCO2.CC1=NC2=C(C=C1)S(=O)(=O)CCC2.CC1=NC2=C(C=C1)S(=O)(=O)CCCO2.CC1=NC2=C(C=C1)S(=O)(=O)CCO2.CC1=NC2=C(C=CC=C2)S1.CC1=NC2=C(N=C1)C(=O)N(C)CC2 SJFRCUMZSJTAEO-UHFFFAOYSA-N 0.000 description 1
- SONINVHJNHTWCQ-UHFFFAOYSA-N CC1=CC2=C(C=N1)C(=O)N(C)C(C)O2.CC1=CC2=C(C=N1)C(=O)N(C)CCO2.CC1=CC2=C(N=C1)C(=O)N(C)CCO2.CC1=NC2=C(C=C1)C(=O)N(C)CCO2.CC1=NC2=C(C=CC=C2)S1.CC1=NC2CC(C)(C)CN(C)C(=O)C2S1.CC1=NC2CC(C)(C)CNC(=O)C2S1.CC1=NC2CCCNC(=O)C2S1 Chemical compound CC1=CC2=C(C=N1)C(=O)N(C)C(C)O2.CC1=CC2=C(C=N1)C(=O)N(C)CCO2.CC1=CC2=C(N=C1)C(=O)N(C)CCO2.CC1=NC2=C(C=C1)C(=O)N(C)CCO2.CC1=NC2=C(C=CC=C2)S1.CC1=NC2CC(C)(C)CN(C)C(=O)C2S1.CC1=NC2CC(C)(C)CNC(=O)C2S1.CC1=NC2CCCNC(=O)C2S1 SONINVHJNHTWCQ-UHFFFAOYSA-N 0.000 description 1
- WMWGSXUOUQZLQA-UHFFFAOYSA-N CC1=CC2=C(C=N1)C(=O)N(C)CCO2.CC1=CC2=C(C=N1)C(=O)NCCO2.CC1=CC2=C(C=N1)S(=O)(=O)CCCO2.CC1=CC2=C(N=C1)C(=O)N(C)CCO2.CC1=CC2=C(N=C1)C(=O)NCCO2.CC1=CC2=C(N=C1)S(=O)(=O)CCCO2.CC1=NC2=C(C=C1)C(=O)N(C)CCO2.CC1=NC2=C(C=C1)C(=O)NCCO2.CC1=NC2=C(C=C1)S(=O)(=O)CCCO2.CC1=NC2=C(N=C1)C(=O)N(C)CCO2.CC1=NC2=C(N=C1)C(=O)NCCO2 Chemical compound CC1=CC2=C(C=N1)C(=O)N(C)CCO2.CC1=CC2=C(C=N1)C(=O)NCCO2.CC1=CC2=C(C=N1)S(=O)(=O)CCCO2.CC1=CC2=C(N=C1)C(=O)N(C)CCO2.CC1=CC2=C(N=C1)C(=O)NCCO2.CC1=CC2=C(N=C1)S(=O)(=O)CCCO2.CC1=NC2=C(C=C1)C(=O)N(C)CCO2.CC1=NC2=C(C=C1)C(=O)NCCO2.CC1=NC2=C(C=C1)S(=O)(=O)CCCO2.CC1=NC2=C(N=C1)C(=O)N(C)CCO2.CC1=NC2=C(N=C1)C(=O)NCCO2 WMWGSXUOUQZLQA-UHFFFAOYSA-N 0.000 description 1
- MIKGHHPELGUYEA-UHFFFAOYSA-N CC1=CC2=C(C=N1)C(=O)NCCO2.CC1=CC2=C(N=C1)C(=O)NCCO2.CC1=NC2=C(C=C1)C(=O)NCCO2.CC1=NC2=C(N=C1)C(=O)N(C)CCO2.CC1=NC2=C(N=C1)C(=O)NCCO2 Chemical compound CC1=CC2=C(C=N1)C(=O)NCCO2.CC1=CC2=C(N=C1)C(=O)NCCO2.CC1=NC2=C(C=C1)C(=O)NCCO2.CC1=NC2=C(N=C1)C(=O)N(C)CCO2.CC1=NC2=C(N=C1)C(=O)NCCO2 MIKGHHPELGUYEA-UHFFFAOYSA-N 0.000 description 1
- XVIBLKRWRUSSPH-UHFFFAOYSA-N CC1=CN=C(NC(=O)C2=CC(O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 XVIBLKRWRUSSPH-UHFFFAOYSA-N 0.000 description 1
- KRURBVQUNMGFGH-UHFFFAOYSA-N CC1=CN=C(NC(=O)C2=CC(OC3CCN(C4CCC4)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(OC3CCN(C4CCC4)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 KRURBVQUNMGFGH-UHFFFAOYSA-N 0.000 description 1
- AIWGCJYCTSSNDX-UHFFFAOYSA-N CC1=CN=C(NC(=O)C2=CC(OC3CCOC3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(OC3CCOC3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 AIWGCJYCTSSNDX-UHFFFAOYSA-N 0.000 description 1
- JFNLBPZUTFBSQA-UHFFFAOYSA-N CC1=CN=C(NC(=O)C2=CC(OCC3=CC=CC=C3)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(OCC3=CC=CC=C3)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 JFNLBPZUTFBSQA-UHFFFAOYSA-N 0.000 description 1
- VMTDDJMMXZADRV-NRFANRHFSA-N CC1=CN=C(NC(=O)C2=CC(OCC3=CC=CC=C3)=CC(O[C@H]3CCN(C)C3=O)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(OCC3=CC=CC=C3)=CC(O[C@H]3CCN(C)C3=O)=C2)C=N1 VMTDDJMMXZADRV-NRFANRHFSA-N 0.000 description 1
- BMZKJYFVIYVMCA-XMMPIXPASA-N CC1=CN=C(NC(=O)C2=CC(O[C@@H]3CCN(C4CC4)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@@H]3CCN(C4CC4)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 BMZKJYFVIYVMCA-XMMPIXPASA-N 0.000 description 1
- KRURBVQUNMGFGH-RUZDIDTESA-N CC1=CN=C(NC(=O)C2=CC(O[C@@H]3CCN(C4CCC4)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@@H]3CCN(C4CCC4)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 KRURBVQUNMGFGH-RUZDIDTESA-N 0.000 description 1
- NFQWDARXNOJTBP-NRFANRHFSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=C(Cl)C4=C(C=C3)C(=O)N(C)CCO4)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=C(Cl)C4=C(C=C3)C(=O)N(C)CCO4)=C2)C=N1 NFQWDARXNOJTBP-NRFANRHFSA-N 0.000 description 1
- NSMWRFVXAQPDGO-QFIPXVFZSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC4=C(C=C3)C(=O)N(C)CCO4)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC4=C(C=C3)C(=O)N(C)CCO4)=C2)C=N1 NSMWRFVXAQPDGO-QFIPXVFZSA-N 0.000 description 1
- UQJVQKMNVZNYOU-NRFANRHFSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC4=C(C=C3)S(=O)(=O)N(C)CCO4)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC4=C(C=C3)S(=O)(=O)N(C)CCO4)=C2)C=N1 UQJVQKMNVZNYOU-NRFANRHFSA-N 0.000 description 1
- RZVLKLFPFJPZTI-FQEVSTJZSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC4=C(C=C3)S(=O)(=O)NCCO4)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC4=C(C=C3)S(=O)(=O)NCCO4)=C2)C=N1 RZVLKLFPFJPZTI-FQEVSTJZSA-N 0.000 description 1
- YEGSKBCIOQCDPH-QFIPXVFZSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C(C(=O)N(C)C)C=C3Cl)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C(C(=O)N(C)C)C=C3Cl)=C2)C=N1 YEGSKBCIOQCDPH-QFIPXVFZSA-N 0.000 description 1
- PMQYBGIFKKGEGB-QHCPKHFHSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)C=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)C=C3)=C2)C=N1 PMQYBGIFKKGEGB-QHCPKHFHSA-N 0.000 description 1
- UCMIAMHGKSFWPG-QHCPKHFHSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)C=C3Cl)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)C=C3Cl)=C2)C=N1 UCMIAMHGKSFWPG-QHCPKHFHSA-N 0.000 description 1
- UNZQWJWYQIUWEM-QFIPXVFZSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 UNZQWJWYQIUWEM-QFIPXVFZSA-N 0.000 description 1
- WENXHRUBHAJIPA-NRFANRHFSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C(S(C)(=O)=O)C=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C(S(C)(=O)=O)C=C3)=C2)C=N1 WENXHRUBHAJIPA-NRFANRHFSA-N 0.000 description 1
- HPHGEUVJQXBNQL-IBGZPJMESA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C(S(C)(=O)=O)N=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C(S(C)(=O)=O)N=C3)=C2)C=N1 HPHGEUVJQXBNQL-IBGZPJMESA-N 0.000 description 1
- QKNWTFGRMUJYFT-NRFANRHFSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C4C(=C3)OCCCS4(=O)=O)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C4C(=C3)OCCCS4(=O)=O)=C2)C=N1 QKNWTFGRMUJYFT-NRFANRHFSA-N 0.000 description 1
- CZMMUYHPALXJIW-NRFANRHFSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C4C(=O)N(C)COC4=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CC=C4C(=O)N(C)COC4=C3)=C2)C=N1 CZMMUYHPALXJIW-NRFANRHFSA-N 0.000 description 1
- UVUXPZWPEMVJFE-NRFANRHFSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CN=C(C(=O)N(C)C)C=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CN=C(C(=O)N(C)C)C=C3)=C2)C=N1 UVUXPZWPEMVJFE-NRFANRHFSA-N 0.000 description 1
- AGHBUATXYPJBMD-IBGZPJMESA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CN=C(C(=O)N(C)C)C=N3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CN=C(C(=O)N(C)C)C=N3)=C2)C=N1 AGHBUATXYPJBMD-IBGZPJMESA-N 0.000 description 1
- GDHXNMWFZKUEJP-NRFANRHFSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=NC=C(C(=O)N4CCC4)C=C3Cl)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=NC=C(C(=O)N4CCC4)C=C3Cl)=C2)C=N1 GDHXNMWFZKUEJP-NRFANRHFSA-N 0.000 description 1
- BMZKJYFVIYVMCA-DEOSSOPVSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C4CC4)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C4CC4)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 BMZKJYFVIYVMCA-DEOSSOPVSA-N 0.000 description 1
- KRURBVQUNMGFGH-VWLOTQADSA-N CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C4CCC4)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 Chemical compound CC1=CN=C(NC(=O)C2=CC(O[C@H]3CCN(C4CCC4)C3=O)=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=C2)C=N1 KRURBVQUNMGFGH-VWLOTQADSA-N 0.000 description 1
- NXDFNZAAEAKRJZ-LJQANCHMSA-N CC1=CSC(NC(=O)C2=CC(O[C@@H]3CCN(C)C3=O)=CC(OC3=CN=C(C(=O)N4CCC4)C=N3)=C2)=N1 Chemical compound CC1=CSC(NC(=O)C2=CC(O[C@@H]3CCN(C)C3=O)=CC(OC3=CN=C(C(=O)N4CCC4)C=N3)=C2)=N1 NXDFNZAAEAKRJZ-LJQANCHMSA-N 0.000 description 1
- XVOOFEWESTVLID-SFHVURJKSA-N CC1=CSC(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CN=C(C(=O)N(C)C)C=N3)=C2)=N1 Chemical compound CC1=CSC(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CN=C(C(=O)N(C)C)C=N3)=C2)=N1 XVOOFEWESTVLID-SFHVURJKSA-N 0.000 description 1
- NXDFNZAAEAKRJZ-IBGZPJMESA-N CC1=CSC(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CN=C(C(=O)N4CCC4)C=N3)=C2)=N1 Chemical compound CC1=CSC(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CN=C(C(=O)N4CCC4)C=N3)=C2)=N1 NXDFNZAAEAKRJZ-IBGZPJMESA-N 0.000 description 1
- RRNHBAJVBJWGAO-KRWDZBQOSA-N CC1=NSC(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CN=C(C(=O)N(C)C)C=N3)=C2)=N1 Chemical compound CC1=NSC(NC(=O)C2=CC(O[C@H]3CCN(C)C3=O)=CC(OC3=CN=C(C(=O)N(C)C)C=N3)=C2)=N1 RRNHBAJVBJWGAO-KRWDZBQOSA-N 0.000 description 1
- UBMWBGWAHIJKOC-UHFFFAOYSA-N CCN1CCC(OC2=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=CC(C(=O)NC3=NC=C(C)N=C3)=C2)C1=O Chemical compound CCN1CCC(OC2=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=CC(C(=O)NC3=NC=C(C)N=C3)=C2)C1=O UBMWBGWAHIJKOC-UHFFFAOYSA-N 0.000 description 1
- UBMWBGWAHIJKOC-HSZRJFAPSA-N CCN1CC[C@@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=CC(C(=O)NC3=NC=C(C)N=C3)=C2)C1=O Chemical compound CCN1CC[C@@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=CC(C(=O)NC3=NC=C(C)N=C3)=C2)C1=O UBMWBGWAHIJKOC-HSZRJFAPSA-N 0.000 description 1
- MPHIECURWATPOV-UHFFFAOYSA-N CCOC(=O)C(CCCS(C)(=O)=O)OC1=CC(OC2=CC=C(C(=O)N3CCC3)N=C2)=CC(C(=O)NC2=NC=C(C)N=C2)=C1 Chemical compound CCOC(=O)C(CCCS(C)(=O)=O)OC1=CC(OC2=CC=C(C(=O)N3CCC3)N=C2)=CC(C(=O)NC2=NC=C(C)N=C2)=C1 MPHIECURWATPOV-UHFFFAOYSA-N 0.000 description 1
- OFNJRYQYELWRRZ-UHFFFAOYSA-N CCOC(=O)C(CCO)OC1=CC(OC2=CC=C(C(=O)N3CCC3)N=C2)=CC(C(=O)NC2=NC=C(C)N=C2)=C1 Chemical compound CCOC(=O)C(CCO)OC1=CC(OC2=CC=C(C(=O)N3CCC3)N=C2)=CC(C(=O)NC2=NC=C(C)N=C2)=C1 OFNJRYQYELWRRZ-UHFFFAOYSA-N 0.000 description 1
- GEYSSLLACAKOFR-HNNXBMFYSA-N CN(C)C(=O)C1=NC=C(OC2=CC(C(=O)O)=CC(O[C@H]3CCN(C)C3=O)=C2)N=C1 Chemical compound CN(C)C(=O)C1=NC=C(OC2=CC(C(=O)O)=CC(O[C@H]3CCN(C)C3=O)=C2)N=C1 GEYSSLLACAKOFR-HNNXBMFYSA-N 0.000 description 1
- JLEXOXYGOPYJNF-UHFFFAOYSA-N CN(CCO)C(=O)C1=CC=C(F)C(Cl)=C1F Chemical compound CN(CCO)C(=O)C1=CC=C(F)C(Cl)=C1F JLEXOXYGOPYJNF-UHFFFAOYSA-N 0.000 description 1
- UZXMRQJHCDKAHQ-UHFFFAOYSA-N CN(CCO)S(=O)(=O)C1=C(F)C=C(F)C=C1 Chemical compound CN(CCO)S(=O)(=O)C1=C(F)C=C(F)C=C1 UZXMRQJHCDKAHQ-UHFFFAOYSA-N 0.000 description 1
- XGVDSRZCNNFRST-UHFFFAOYSA-N CN(CCO)S(=O)(=O)C1=C(F)C=C(F)C=C1.CN1CCOC2=C(C=CC(F)=C2)S1(=O)=O Chemical compound CN(CCO)S(=O)(=O)C1=C(F)C=C(F)C=C1.CN1CCOC2=C(C=CC(F)=C2)S1(=O)=O XGVDSRZCNNFRST-UHFFFAOYSA-N 0.000 description 1
- NFFDSZJZQBYUKM-UHFFFAOYSA-N CN1CCC(Br)C1=O Chemical compound CN1CCC(Br)C1=O NFFDSZJZQBYUKM-UHFFFAOYSA-N 0.000 description 1
- MSTSHCGQIYYBSJ-UHFFFAOYSA-N CN1CCOC2=C(C=CC(F)=C2)S1(=O)=O Chemical compound CN1CCOC2=C(C=CC(F)=C2)S1(=O)=O MSTSHCGQIYYBSJ-UHFFFAOYSA-N 0.000 description 1
- CTEBEGRPFDCLGB-MRXNPFEDSA-N CN1CC[C@@H](OC2=CC(OC3=CN=C(C(=O)N4CCC4)C=N3)=CC(C(=O)O)=C2)C1=O Chemical compound CN1CC[C@@H](OC2=CC(OC3=CN=C(C(=O)N4CCC4)C=N3)=CC(C(=O)O)=C2)C1=O CTEBEGRPFDCLGB-MRXNPFEDSA-N 0.000 description 1
- FQIXGYQTVVHCFY-DEOSSOPVSA-N CN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)C=C3)=CC(C(=O)NC3=NN(C(=O)OC(C)(C)C)C=C3)=C2)C1=O Chemical compound CN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)C=C3)=CC(C(=O)NC3=NN(C(=O)OC(C)(C)C)C=C3)=C2)C1=O FQIXGYQTVVHCFY-DEOSSOPVSA-N 0.000 description 1
- WXPPTBPCARYXQY-NRFANRHFSA-N CN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)C=C3)=CC(C(=O)NC3=NNC=C3)=C2)C1=O Chemical compound CN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)C=C3)=CC(C(=O)NC3=NNC=C3)=C2)C1=O WXPPTBPCARYXQY-NRFANRHFSA-N 0.000 description 1
- WAACOJQBXYHFHP-IBGZPJMESA-N CN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)C=C3)=CC(C(=O)O)=C2)C1=O Chemical compound CN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)C=C3)=CC(C(=O)O)=C2)C1=O WAACOJQBXYHFHP-IBGZPJMESA-N 0.000 description 1
- SKXIUFDSCLOSGM-QFIPXVFZSA-N CN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=CC(C(=O)NC3=NC=CC=C3)=C2)C1=O Chemical compound CN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=CC(C(=O)NC3=NC=CC=C3)=C2)C1=O SKXIUFDSCLOSGM-QFIPXVFZSA-N 0.000 description 1
- HDWRRRHRTWGYSQ-NRFANRHFSA-N CN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=CC(C(=O)NC3=NC=CN=C3)=C2)C1=O Chemical compound CN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=CC(C(=O)NC3=NC=CN=C3)=C2)C1=O HDWRRRHRTWGYSQ-NRFANRHFSA-N 0.000 description 1
- WPVWLZCHMHNEQB-SFHVURJKSA-N CN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=CC(C(=O)O)=C2)C1=O Chemical compound CN1CC[C@H](OC2=CC(OC3=CC=C(C(=O)N4CCC4)N=C3)=CC(C(=O)O)=C2)C1=O WPVWLZCHMHNEQB-SFHVURJKSA-N 0.000 description 1
- YOOWUBKMBHAUIG-QFIPXVFZSA-N CN1CC[C@H](OC2=CC(OC3=CC=C4C(=C3)OCCCS4(=O)=O)=CC(C(=O)NC3=NN(C(=O)OC(C)(C)C)C=C3)=C2)C1=O Chemical compound CN1CC[C@H](OC2=CC(OC3=CC=C4C(=C3)OCCCS4(=O)=O)=CC(C(=O)NC3=NN(C(=O)OC(C)(C)C)C=C3)=C2)C1=O YOOWUBKMBHAUIG-QFIPXVFZSA-N 0.000 description 1
- IVCRYQOCEQPNNJ-IBGZPJMESA-N CN1CC[C@H](OC2=CC(OC3=CC=C4C(=C3)OCCCS4(=O)=O)=CC(C(=O)NC3=NNC=C3)=C2)C1=O Chemical compound CN1CC[C@H](OC2=CC(OC3=CC=C4C(=C3)OCCCS4(=O)=O)=CC(C(=O)NC3=NNC=C3)=C2)C1=O IVCRYQOCEQPNNJ-IBGZPJMESA-N 0.000 description 1
- CTEBEGRPFDCLGB-INIZCTEOSA-N CN1CC[C@H](OC2=CC(OC3=CN=C(C(=O)N4CCC4)C=N3)=CC(C(=O)O)=C2)C1=O Chemical compound CN1CC[C@H](OC2=CC(OC3=CN=C(C(=O)N4CCC4)C=N3)=CC(C(=O)O)=C2)C1=O CTEBEGRPFDCLGB-INIZCTEOSA-N 0.000 description 1
- NVTRMUNZCMMMLE-KRWDZBQOSA-N CN1CC[C@H](OC2=CC(OCC3=CC=CC=C3)=CC(C(=O)O)=C2)C1=O Chemical compound CN1CC[C@H](OC2=CC(OCC3=CC=CC=C3)=CC(C(=O)O)=C2)C1=O NVTRMUNZCMMMLE-KRWDZBQOSA-N 0.000 description 1
- HDGWFTVUCOOVNT-UHFFFAOYSA-N CN1COC2=C(C=CC(F)=C2)C1=O Chemical compound CN1COC2=C(C=CC(F)=C2)C1=O HDGWFTVUCOOVNT-UHFFFAOYSA-N 0.000 description 1
- FIRJRGJQUTXFBC-UHFFFAOYSA-N CN1COC2=C(C=CC(F)=C2)C1=O.CNC(=O)C1=C(O)C=C(F)C=C1 Chemical compound CN1COC2=C(C=CC(F)=C2)C1=O.CNC(=O)C1=C(O)C=C(F)C=C1 FIRJRGJQUTXFBC-UHFFFAOYSA-N 0.000 description 1
- NEBKDKZDEROXPG-IBGZPJMESA-N CN1COC2=C(C=CC(OC3=CC(C(=O)NC4=NNC=C4)=CC(O[C@H]4CCN(C)C4=O)=C3)=C2)C1=O Chemical compound CN1COC2=C(C=CC(OC3=CC(C(=O)NC4=NNC=C4)=CC(O[C@H]4CCN(C)C4=O)=C3)=C2)C1=O NEBKDKZDEROXPG-IBGZPJMESA-N 0.000 description 1
- FQISCPCTONXQJP-KRWDZBQOSA-N CN1COC2=CC(OC3=CC(C(=O)O)=CC(O[C@H]4CCN(C)C4=O)=C3)=CC=C2C1=O Chemical compound CN1COC2=CC(OC3=CC(C(=O)O)=CC(O[C@H]4CCN(C)C4=O)=C3)=CC=C2C1=O FQISCPCTONXQJP-KRWDZBQOSA-N 0.000 description 1
- HPCYZQZHUNXJPG-UHFFFAOYSA-N CNC(=O)C(Br)CCBr Chemical compound CNC(=O)C(Br)CCBr HPCYZQZHUNXJPG-UHFFFAOYSA-N 0.000 description 1
- DGHUWJXRAAGAJR-UHFFFAOYSA-N CNC(=O)C1=CC=C(F)C=C1O Chemical compound CNC(=O)C1=CC=C(F)C=C1O DGHUWJXRAAGAJR-UHFFFAOYSA-N 0.000 description 1
- BQGVPHASEPSSFI-LLVKDONJSA-N COC(=O)C1=CC(O[C@@H]2CCN(C)C2=O)=CC(O)=C1 Chemical compound COC(=O)C1=CC(O[C@@H]2CCN(C)C2=O)=CC(O)=C1 BQGVPHASEPSSFI-LLVKDONJSA-N 0.000 description 1
- YVLYGZNTGFFNBH-QGZVFWFLSA-N COC(=O)C1=CC(O[C@@H]2CCN(C)C2=O)=CC(OC2=CN=C(C(=O)N3CCC3)C=N2)=C1 Chemical compound COC(=O)C1=CC(O[C@@H]2CCN(C)C2=O)=CC(OC2=CN=C(C(=O)N3CCC3)C=N2)=C1 YVLYGZNTGFFNBH-QGZVFWFLSA-N 0.000 description 1
- VIRCJHXCIJZYFM-GOSISDBHSA-N COC(=O)C1=CC(O[C@@H]2CCN(C)C2=O)=CC(OCC2=CC=CC=C2)=C1 Chemical compound COC(=O)C1=CC(O[C@@H]2CCN(C)C2=O)=CC(OCC2=CC=CC=C2)=C1 VIRCJHXCIJZYFM-GOSISDBHSA-N 0.000 description 1
- BQGVPHASEPSSFI-NSHDSACASA-N COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(O)=C1 Chemical compound COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(O)=C1 BQGVPHASEPSSFI-NSHDSACASA-N 0.000 description 1
- WREQWQZPAMZWPY-FQEVSTJZSA-N COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CC=C(C(=O)N3CCC3)C=C2)=C1 Chemical compound COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CC=C(C(=O)N3CCC3)C=C2)=C1 WREQWQZPAMZWPY-FQEVSTJZSA-N 0.000 description 1
- SMFBVLBQZIDZIA-FQEVSTJZSA-N COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CC=C(C(=O)N3CCC3)C=C2Cl)=C1 Chemical compound COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CC=C(C(=O)N3CCC3)C=C2Cl)=C1 SMFBVLBQZIDZIA-FQEVSTJZSA-N 0.000 description 1
- KXQRHPKFNWKPNL-SFHVURJKSA-N COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CC=C3C(=C2)OCCCS3(=O)=O)=C1 Chemical compound COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CC=C3C(=C2)OCCCS3(=O)=O)=C1 KXQRHPKFNWKPNL-SFHVURJKSA-N 0.000 description 1
- SNNAUEPYRZGYTI-SFHVURJKSA-N COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CC=C3C(=O)N(C)COC3=C2)=C1 Chemical compound COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CC=C3C(=O)N(C)COC3=C2)=C1 SNNAUEPYRZGYTI-SFHVURJKSA-N 0.000 description 1
- MFNMCVJIOOKEQZ-INIZCTEOSA-N COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CN=C(C(=O)N(C)C)C=N2)=C1 Chemical compound COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CN=C(C(=O)N(C)C)C=N2)=C1 MFNMCVJIOOKEQZ-INIZCTEOSA-N 0.000 description 1
- LMNSUDJGZAQNFZ-IBGZPJMESA-N COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CN=C(C(=O)N3CCC3)C=C2)=C1 Chemical compound COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CN=C(C(=O)N3CCC3)C=C2)=C1 LMNSUDJGZAQNFZ-IBGZPJMESA-N 0.000 description 1
- YVLYGZNTGFFNBH-KRWDZBQOSA-N COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CN=C(C(=O)N3CCC3)C=N2)=C1 Chemical compound COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OC2=CN=C(C(=O)N3CCC3)C=N2)=C1 YVLYGZNTGFFNBH-KRWDZBQOSA-N 0.000 description 1
- VIRCJHXCIJZYFM-SFHVURJKSA-N COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OCC2=CC=CC=C2)=C1 Chemical compound COC(=O)C1=CC(O[C@H]2CCN(C)C2=O)=CC(OCC2=CC=CC=C2)=C1 VIRCJHXCIJZYFM-SFHVURJKSA-N 0.000 description 1
- WHEBPDAUUHSTGI-UHFFFAOYSA-N Cc(cc1)nc(OCCN2)c1C2=O Chemical compound Cc(cc1)nc(OCCN2)c1C2=O WHEBPDAUUHSTGI-UHFFFAOYSA-N 0.000 description 1
- HXGKRLFBZBGXCP-UHFFFAOYSA-N Cc(nc1)cc(OCCN2)c1C2=O Chemical compound Cc(nc1)cc(OCCN2)c1C2=O HXGKRLFBZBGXCP-UHFFFAOYSA-N 0.000 description 1
- WODOTCHAPSNEHI-UHFFFAOYSA-N Cc1cc(OCCNC2=O)c2nc1 Chemical compound Cc1cc(OCCNC2=O)c2nc1 WODOTCHAPSNEHI-UHFFFAOYSA-N 0.000 description 1
- BETYWNJUFJWDGH-UHFFFAOYSA-N Cc1nc(OCCN(C)C2=O)c2nc1 Chemical compound Cc1nc(OCCN(C)C2=O)c2nc1 BETYWNJUFJWDGH-UHFFFAOYSA-N 0.000 description 1
- POQZGLQRFOHJPU-UHFFFAOYSA-N Cc1nc(OCCNC2=O)c2nc1 Chemical compound Cc1nc(OCCNC2=O)c2nc1 POQZGLQRFOHJPU-UHFFFAOYSA-N 0.000 description 1
- APBKCBCPVSDREM-UHFFFAOYSA-N FC1=CC(F)=C(SCCCOC2CCCCO2)C=C1 Chemical compound FC1=CC(F)=C(SCCCOC2CCCCO2)C=C1 APBKCBCPVSDREM-UHFFFAOYSA-N 0.000 description 1
- GSAYYRGLSUPYOC-UHFFFAOYSA-N FC1=CC2=C(C=C1)SCCCO2 Chemical compound FC1=CC2=C(C=C1)SCCCO2 GSAYYRGLSUPYOC-UHFFFAOYSA-N 0.000 description 1
- IKOBNRGCSHDXFP-UHFFFAOYSA-N O=C(C1=CC=C(Br)C=N1)N1CCC1 Chemical compound O=C(C1=CC=C(Br)C=N1)N1CCC1 IKOBNRGCSHDXFP-UHFFFAOYSA-N 0.000 description 1
- GWHOHYFPQOVKNS-UHFFFAOYSA-N O=C(C1=CN=C(Cl)C(Cl)=C1)N1CCC1 Chemical compound O=C(C1=CN=C(Cl)C(Cl)=C1)N1CCC1 GWHOHYFPQOVKNS-UHFFFAOYSA-N 0.000 description 1
- WIFSSWYPPHSSIV-UHFFFAOYSA-N O=C(C1=CN=C(Cl)C=N1)N1CCC1 Chemical compound O=C(C1=CN=C(Cl)C=N1)N1CCC1 WIFSSWYPPHSSIV-UHFFFAOYSA-N 0.000 description 1
- WJELXFTXLUJSPG-UHFFFAOYSA-N O=C(O)C1=CC(OCC2=CC=CC=C2)=CC(OC2=CN=C(C(=O)N3CCC3)C=C2)=C1 Chemical compound O=C(O)C1=CC(OCC2=CC=CC=C2)=CC(OC2=CN=C(C(=O)N3CCC3)C=C2)=C1 WJELXFTXLUJSPG-UHFFFAOYSA-N 0.000 description 1
- FXJOTWLLDJYKAG-UHFFFAOYSA-N O=C(O)C1=CN=C(Cl)C=N1 Chemical compound O=C(O)C1=CN=C(Cl)C=N1 FXJOTWLLDJYKAG-UHFFFAOYSA-N 0.000 description 1
- XXRKQVTVRFABQY-UHFFFAOYSA-N O=S1(=O)CCCOC2=C1C=CC(F)=C2 Chemical compound O=S1(=O)CCCOC2=C1C=CC(F)=C2 XXRKQVTVRFABQY-UHFFFAOYSA-N 0.000 description 1
- XAWOFYZQYVUNND-UHFFFAOYSA-N OCCCSC1=C(F)C=C(F)C=C1 Chemical compound OCCCSC1=C(F)C=C(F)C=C1 XAWOFYZQYVUNND-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to a group of benzoyl amino heterocyclyl compounds which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
- GLK or GK glucokinase
- the compounds are predicted to lower blood glucose by increasing hepatic glucose uptake.
- Such compounds may have utility in the treatment of Type 2 diabetes and obesity.
- the invention also relates to pharmaceutical compositions comprising said compounds and to methods of treatment of diseases mediated by GLK using said compounds.
- the main plasma membrane glucose transporter is GLUT2.
- G-6-P glucose-6-phosphate
- GLK glucokinase
- GLK has a high (6-10 mM) Km for glucose and is not inhibited by physiological concentrations of G-6-P [1].
- GLK expression is limited to a few tissues and cell types, most notably pancreatic ⁇ -cells and liver cells (hepatocytes) [1].
- GLK activity is rate limiting for glucose utilisation and therefore regulates the extent of glucose induced insulin secretion and hepatic glycogen synthesis. These processes are critical in the maintenance of whole body glucose homeostasis and both are dysfunctional in diabetes [2].
- Maturity-Onset Diabetes of the Young Type 2 the diabetes is caused by GLK loss of function mutations [3,4].
- Hyperglycaemia in MODY-2 patients results from defective glucose utilisation in both the pancreas and liver [5].
- Defective glucose utilisation in the pancreas of MODY-2 patients results in a raised threshold for glucose stimulated insulin secretion.
- rare activating mutations of GLK reduce this threshold resulting in familial hyperinsulinism [6, 6a, 7].
- hepatic glucokinase activity is also decreased in type 2 diabetics [8].
- GLK global or liver selective overexpression of GLK prevents or reverses the development of the diabetic phenotype in both dietary and genetic models of the disease [9-12].
- acute treatment of type 2 diabetics with fructose improves glucose tolerance through stimulation of hepatic glucose utilisation [1,3]. This effect is believed to be mediated through a fructose induced increase in cytosolic GLK activity in the hepatocyte by the mechanism described below [13].
- GLK regulatory protein GLK regulatory protein
- F6P fructose-6-phosphate
- F1P fructose-1-phosphate
- FIP is generated by fructokinase mediated phosphorylation of dietary fructose. Consequently, GLK/GLKRP complex integrity and hepatic GLK activity is regulated in a nutritionally dependent manner as F6P is dominant in the post-absorptive state whereas FIP predominates in the post-prandial state.
- the pancreatic ⁇ -cell expresses GLK in the absence of GLKRP. Therefore, ⁇ -cell GLK activity is regulated extensively by the availability of its substrate, glucose. Small molecules may activate GLK either directly or through destabilising the GLK/GLKRP complex.
- the former class of compounds are predicted to stimulate glucose utilisation in both the liver and the pancreas whereas the latter are predicted to act selectively in the liver.
- compounds with either profile are predicted to be of therapeutic benefit in treating Type 2 diabetes as this disease is characterised by defective glucose utilisation in both tissues.
- GLK, GLKRP and the K ATP channel are expressed in neurones of the hypothalamus, a region of the brain that is important in the regulation of energy balance and the control of food intake [14-18]. These neurones have been shown to express orectic and anorectic neuropeptides [15, 19, 20] and have been assumed to be the glucose-sensing neurones within the hypothalamus that are either inhibited or excited by changes in ambient glucose concentrations [17, 19, 21, 22]. The ability of these neurones to sense changes in glucose levels is defective in a variety of genetic and experimentally induced models of obesity [23-28].
- GLK activators may decrease food intake and weight gain through central effects on GLK. Therefore, GLK activators may be of therapeutic use in treating eating disorders, including obesity, in addition to diabetes.
- the hypothalamic effects will be additive or synergistic to the effects of the same compounds acting in the liver and/or pancreas in normalising glucose homeostasis, for the treatment of Type 2 diabetes.
- the GLK/GLKRP system can be described as a potential “Diabesity” target (of benefit in both Diabetes and Obesity).
- GLK is also expressed in specific entero-endocrine cells where it is believed to control the glucose sensitive secretion of the incretin peptides GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (Glucagon-Like Peptide-1) from gut K-cells and L-cells respectively (32, 33, 34). Therefore, small molecule activators of GLK may have additional beneficial effects on insulin secretion, b-cell function and survival and body weight as a consequence of stimulating GIP and GLP-1 secretion from these entero-endocrine cells.
- GIP glucose sensitive secretion of the incretin peptides
- GLP-1 Glucagon-Like Peptide-1
- glucokinase activators In WO00/58293 and WO01/44216 (Roche), a series of benzylcarbamoyl compounds are described as glucokinase activators. The mechanism by which such compounds activate GLK is assessed by measuring the direct effect of such compounds in an assay in which GLK activity is linked to NADH production, which in turn is measured optically—see details of the in vitro assay described hereinafter.
- Compounds of the present invention may activate GLK directly or may activate GLK by inhibiting the interaction of GLKRP with GLK.
- GLK activators have been described in WO03/095438 (substituted phenylacetamides, Roche), WO03/055482 (carboxamide and sulphonamide derivatives, Novo Nordisk), WO2004/002481 (arylcarbonyl derivatives, Novo Nordisk), and in WO03/080585 (amino-substituted benzoylaminoheterocycles, Banyu).
- WO03/000267 describes a group of benzoyl amino pyridyl carboxylic acids which are activators of the enzyme glucokinase (GLK).
- R 3 is a phenyl or a substituted heterocycle other than a carboxylic acid substituted pyridyl.
- the compounds of the invention may have favourable metabolic profiles and/or toxicity profiles.
- the compounds of the invention may also have superior potency and/or advantageous physical properties (as described above) and/or favourable toxicity profiles and/or favourable metabolic profiles in comparison with other GLK activators known in the art, as well as those described in WO 03/015774.
- R 4 is selected from hydrogen, (1-4C)alkyl [optionally substituted by 1 or 2 substituents independently selected from HET-5, —OR 5 , —SO 2 R 5 , (3-6C)cycloalkyl (optionally substituted with 1 group selected from R 15 ) and —C(O)NR 5 R 5 ], (3-6C)cycloalkyl (optionally substituted with 1 group selected from R 15 ) and HET-5;
- R 5 is hydrogen or (1-4C)alkyl
- R 4 and R 5 together with the nitrogen atom to which they are attached form a 4 to 7 membered saturated or partially unsaturated heterocyclyl ring, optionally containing 1 or 2 further heteroatoms (in addition to the linking N atom) independently selected from O, N and S, wherein a —CH 2 — group can optionally be replaced by a —C(O)— and wherein a sulphur atom in the ring may optionally be oxidised to a S(O) or S(O) 2 group; which ring is optionally substituted on an available carbon atom by 1 or 2 substituents independently selected from R 8 and/or on an available nitrogen atom by a substituent selected from R 9 ; or
- heterocyclyl group HET-1 encompass heteroaryl rings which may be substituted on nitrogen, such substitution may not result in charged quaternary nitrogen atoms, removal of aromaticity of the ring or unstable structures. It will be appreciated that the definition of HET-1 is not intended to include any O—O, O—S or S—S bonds. It will be appreciated that the definition of HET-1 is not intended to include unstable structures.
- any single carbon atom in HET-1 may only be substituted by one group R 6 in order to maintain aromaticity of the ring.
- Up to two different carbon atoms in a HET-1 ring may be substituted by an R 6 group, each of which may be the same or different, provided the structure thereby formed is stable and aromatic.
- R 8 can be present on any or all available carbon atoms in the heterocyclic ring formed by NR 4 R 5 ; each carbon atom can be substituted with 1 or 2 R 8 groups which may be the same or different, provided the structure thereby formed is stable (so, for example, it is not intended to cover gem-dihydroxy substitution).
- Compounds of Formula (I) may form salts which are within the ambit of the invention.
- Pharmaceutically acceptable salts are preferred although other salts may be useful in, for example, isolating or purifying compounds.
- the invention relates to compounds of formula (I) as hereinabove defined or to a pharmaceutically acceptable salt.
- the invention relates to compounds of formula (I) as hereinabove defined or to a pro-drug thereof.
- Suitable examples of pro-drugs of compounds of formula (I) are in-vivo hydrolysable esters of compounds of formula (I). Therefore in another aspect, the invention relates to compounds of formula (I) as hereinabove defined or to an in-vivo hydrolysable ester thereof.
- alkyl includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as “propyl” are specific for the straight chain version only and references to individual branched-chain alkyl groups such as t-butyl are specific for the branched chain version only. For example, “(1-4C)alkyl” includes methyl, ethyl, propyl, isopropyl and t-butyl. An analogous convention applies to other generic terms.
- HET-1 containing a nitrogen in the 2-position is intended to refer to the 2-position relative to the amide nitrogen atom to which the group is attached.
- HET-1 encompasses but is not limited to the heterocycles shown in the following structures:
- HET-1 as a 5- or 6-membered, C-linked heteroaryl ring as hereinbefore defined, include thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl and triazolyl.
- HET-2 examples include thienyl, furyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl and triazolyl.
- Further suitable examples of HET-2 include aromatic heterocycles where a ring nitrogen or sulfur atom has been oxidised but aromaticity has been preserved, for example a pyridine N-oxide.
- Further suitable examples of HET-2 include thiazolyl, pyridyl, pyrazinyl, pyridazinyl and pyrimidinyl.
- Suitable examples for a 4-7 membered ring formed by R 4 and R 5 together with the nitrogen to which they are attached include morpholino, thiomorpholino (and versions thereof wherein the sulfur is oxidised to an SO or S(O) 2 group), piperidinyl, piperazinyl, pyrrolidinyl, azetidinyl, homopiperazinyl, homo-morpholino, homo-thiomorpholino (and versions thereof wherein the sulfur is oxidised to an SO or S(O) 2 group) and homo-piperidinyl.
- Suitable examples for a 6-10 membered bicyclic heterocyclic ring formed by R 4 and R 5 together with the nitrogen to which they are attached, as hereinbefore defined, are bicyclic saturated or partially unsaturated heterocyclyl ring such as those illustrated by the structures shown below (wherein the dotted line indicates the point of attachment to the rest of the molecule and wherein R represents the optional substituents on carbon or nitrogen defined hereinbefore):
- a ring system is a [2.2.1] system such as
- such a ring system is a [2.1.1] system such as
- Suitable values for the bicyclic system HET-3 formed by ring B fused to Ring C include those where Ring C is pyridyl, pyrazinyl, pyrimidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, homothiomorpholinyl, oxathianyl, homooxathianyl, furyl, thienyl, pyrrolyl, pyrrolidinyl, 1,3-dioxolanyl, oxazolyl, thiazolyl, imidazolyl, imidazolidinyl, pyrazolyl, isoxazolyl, isothiazolyl, pyranyl, 1,4-dioxolanyl, dihydrothienyl, dihydrofuryl and oxathiazepinyl. Further suitable values include those wherein Ring C is oxathiazepin
- Ring C have been oxidised to a carbonyl group
- sulfur atoms in Ring C have been oxidised to an S(O) or S(O) 2 group.
- Ring B as a 5- or 6-membered heterocyclyl ring are furyl, thienyl, pyrrolyl, pyrrolidinyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl.
- Further suitable values for Ring B are thiazolyl, pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl.
- Still further suitable values for Ring B are thiazolyl and pyridyl.
- Ring B is phenyl.
- HET-3 may suitably be selected from the structures below (which may optionally be substituted as hereinbefore defined):
- suitable values for HET-3 are ring systems where Ring C is a 7-membered ring, for example:
- HET-3 includes the following formulae A to F, wherein each R 12a is independently hydrogen or is R 12 as hereinbefore defined, each R 13a is independently hydrogen or is R 13 as hereinbefore defined, each R 14a is independently hydrogen or is R 14 as hereinbefore defined:
- HET-3 Further suitable values for HET-3 include formulae G to P as follows:
- Ring C as 1,3-dioxolyl are intended to refer to structures such as the following (illustrated with Ring B is phenyl):
- Ring C as 1,4-dioxolanyl are intended to refer to structures such as the following (illustrated with Ring B is phenyl):
- suitable values for the bicyclic system formed by Ring C fused to Ring B as phenyl include the following (wherein each R 13a is hydrogen or is selected from R 13 as hereinbefore defined, R 14a is hydrogen or is selected from R 14 as hereinbefore defined and each R 12a is hydrogen or is R 12 as hereinbefore defined):
- the bicyclic system formed by Ring C fused to Ring B as phenyl is selected from formulae AA to MM (wherein R 12a is hydrogen or is selected from R 12 as hereinbefore defined, R 13a is hydrogen or is selected from R 13 as hereinbefore defined and each R 14a is hydrogen or R 14 as hereinbefore defined):
- the bicyclic system formed by Ring C fused to Ring B as phenyl is selected from:
- R 13a is hydrogen or is methyl and R 12a is hydrogen or is R 12 as hereinbefore defined, for example R 12a is hydrogen or fluoro, or for example R 12a is hydrogen.
- the bicyclic system formed by Ring C fused to Ring B as phenyl is selected from
- R 14a are hydrogen
- R 13a is hydrogen or is methyl
- R 12a is hydrogen or is R 12 as hereinbefore defined, for example R 12a is hydrogen or fluoro, or for example R 12a is hydrogen.
- the bicyclic system formed by Ring C fused to Ring B as phenyl is of formula EE.
- the bicyclic system formed by Ring C fused to Ring B as phenyl is of formula FF.
- the bicyclic system formed by Ring C fused to Ring B as phenyl is of formula GG.
- the bicyclic system formed by Ring C fused to Ring B as phenyl is of formula HH.
- the bicyclic system formed by Ring C fused to Ring B as phenyl is of formula (Z):
- R z is hydrogen or fluoro
- Z 1 is CH 2 or NR 13a
- R 13a is hydrogen or methyl
- Z 2 is C( ⁇ O) or SO 2 .
- Ring C is an optionally substituted 5-7 membered heterocyclic ring fused to the benzene ring, containing 1, 2 or 3 ring hetereoatoms independently selected from O, S and N (provided that there are no O—O, S—O or S—S bonds within the ring), wherein any ring carbon or sulfur atom may optionally be oxidised, provided that where Ring C contains two ring heteroatoms they are not both oxygen (such that for example, Ring C is not dioxolyl or dioxolanyl).
- HET-4 examples include thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl and triazolyl.
- HET-5 can be a saturated, or partially or fully unsaturated ring.
- HET-5 examples include azetidinyl, furyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, morpholino, morpholinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyrrolyl, pyrrolidinyl, pyrrolidonyl, 2,5-dioxopyrrolidinyl, 1,1-dioxotetrahydrothienyl, 2-oxoimidazolidinyl, 2,4-dioxoimidazolidinyl, 2-oxo-1,3,4-(4-triazolinyl), 2-oxazolidin
- HET-5 may be linked by any appropriate available C or N atom, therefore for example, for HET-5 as “imidazolyl” includes 1-, 2-, 4- and 5-imidazolyl.
- Examples of (1-4C)alkyl include methyl, ethyl, propyl, isopropyl, butyl and tert-butyl; examples of (3-6C)cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; examples of halo include fluoro, chloro, bromo and iodo; examples of hydroxy(1-4C)alkyl include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-hydroxyisopropyl and 4-hydroxybutyl; examples of (1-4C)alkoxy(1-4C)alkyl include methoxymethyl, ethoxymethyl, tert-butoxymethyl, 2-methoxyethyl, 2-ethoxyethyl, methoxypropyl, 2-methoxypropyl and methoxybutyl; example of (1-4C)alkoxy include methoxy, eth
- the invention includes in its definition any such optically active or racemic form which possesses the property of stimulating GLK directly or inhibiting the GLK/GLKRP interaction.
- the synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form.
- certain compounds may exist in tautomeric forms and that the invention also relates to any and all tautomeric forms of the compounds of the invention which activate GLK.
- the compound of formula (I) has the (S)-configuration at the pyrrolidone ring and is thereby a compound of formula (IA):
- the compound of formula (I) has the (R)-configuration at the pyrrolidone ring and is thereby a compound of formula (IB):
- compounds of formula (I) in an alternative embodiment are provided pharmaceutically-acceptable salts of compounds of formula (I), in a further alternative embodiment are provided in-vivo hydrolysable esters of compounds of formula (I), and in a further alternative embodiment are provided pharmaceutically-acceptable salts of in-vivo hydrolysable esters of compounds of formula (I).
- each variable group are as follows. Such values may be used where appropriate with any of the values, definitions, claims, aspects or embodiments defined hereinbefore or hereinafter. In particular, each may be used as an individual limitation on the broadest definition of formulae (I), (TI), (III) and/or (IV), as appropriate. Further, each of the following values may be used in combination with one or more of the other following values to limit the broadest defintion of formulae (I), (II), (III) and/or (IV), as appropriate.
- the compounds of the invention may be administered in the form of a pro-drug.
- a pro-drug is a bioprecursor or pharmaceutically acceptable compound being degradable in the body to produce a compound of the invention (such as an ester or amide of a compound of the invention, particularly an in-vivo hydrolysable ester).
- a prodrug is a bioprecursor or pharmaceutically acceptable compound being degradable in the body to produce a compound of the invention (such as an ester or amide of a compound of the invention, particularly an in-vivo hydrolysable ester).
- Various forms of prodrugs are known in the art. For examples of such prodrug derivatives, see:
- pro-drugs examples include as follows.
- An in-vivo hydrolysable ester of a compound of the invention containing a carboxy or a hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
- Suitable pharmaceutically-acceptable esters for carboxy include C 1 to C 6 alkoxymethyl esters for example methoxymethyl, C 1 to C 6 alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C 3 to C 8 cycloalkoxycarbonyloxyC 1 to C 6 alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters, for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C 1-6 alkoxycarbonyloxyethyl esters.
- An in-vivo hydrolysable ester of a compound of the invention containing a hydroxy group includes inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in-vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s.
- inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in-vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s.
- ⁇ -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy.
- a selection of in-vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.
- compounds of Formula (I) may form pharmaceutically acceptable salts.
- a suitable pharmaceutically-acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.
- a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
- an alkali metal salt for example a sodium or potassium salt
- an alkaline earth metal salt for example a calcium or magnesium salt
- an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation
- a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxye
- a further feature of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising a compound of Formula (I) as defined above, or a pharmaceutically-acceptable salt thereof, together with a pharmaceutically-acceptable diluent or carrier.
- a compound of Formula (I), or a pharmaceutically-acceptable salt thereof as defined above for use as a medicament for treatment of a disease mediated through GLK, in particular type 2 diabetes.
- a compound of Formula (I) or a pharmaceutically-acceptable salt thereof in the preparation of a medicament for treatment of a disease mediated through GLK, in particular type 2 diabetes.
- the compound is suitably formulated as a pharmaceutical composition for use in this way.
- a method of treating GLK mediated diseases, especially diabetes by administering an effective amount of a compound of Formula (I) or a pharmaceutically-acceptable salt thereof, to a mammal in need of such treatment.
- Specific diseases which may be treated by a compound or composition of the invention include: blood glucose lowering in Type 2 Diabetes Mellitus without a serious risk of hypoglycaemia (and potential to treat type 1), dyslipidemia, obesity, insulin resistance, metabolic syndrome X, impaired glucose tolerance.
- the GLK/GLKRP system can be described as a potential “Diabesity” target (of benefit in both Diabetes and Obesity).
- a compound of Formula (I) or a pharmaceutically-acceptable salt thereof in the preparation of a medicament for use in the combined treatment or prevention, particularly treatment, of diabetes and obesity.
- a method for the combined treatment of obesity and diabetes by administering an effective amount of a compound of Formula (I) or a pharmaceutically-acceptable salt thereof, to a mammal in need of such treatment.
- a compound of Formula (I) or a pharmaceutically-acceptable salt thereof as defined above for use as a medicament for treatment or prevention, particularly treatment of obesity.
- a method for the treatment of obesity by administering an effective amount of a compound of Formula (I) or a pharmaceutically-acceptable salt thereof, to a mammal in need of such treatment.
- Compounds of the invention may be particularly suitable for use as pharmaceuticals because of advantageous physical and/or pharmacokinetic properties, and/or favourable toxicity profile.
- compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing). Dosage forms suitable for oral use are preferred.
- compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
- compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
- Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
- inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate
- granulating and disintegrating agents such as corn starch or algenic acid
- binding agents such as starch
- lubricating agents
- Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil such as peanut oil, liquid paraffin, or olive oil.
- Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol
- the aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
- preservatives such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin).
- the oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.
- the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these.
- Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening, flavouring and preservative agents.
- Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
- sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
- compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above.
- a sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
- Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets.
- Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
- the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
- a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
- Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient.
- the size of the dose for therapeutic or prophylactic purposes of a compound of the Formula (I) will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.
- a daily dose in the range for example, 0.5 mg to 75 mg per kg body weight is received, given if required in divided doses.
- a parenteral route is employed.
- a dose in the range for example, 0.5 mg to 30 mg per kg body weight will generally be used.
- a dose in the range for example, 0.5 mg to 25 mg per kg body weight will be used.
- Oral administration is however preferred.
- the elevation of GLK activity described herein may be applied as a sole therapy or in combination with one or more other substances and/or treatments for the indication being treated. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. Simultaneous treatment may be in a single tablet or in separate tablets.
- chemotherapy may include the following main categories of treatment:
- a compound of the invention, or a salt thereof may be prepared by any process known to be applicable to the preparation of such compounds or structurally related compounds.
- Functional groups may be protected and deprotected using conventional methods.
- protecting groups such as amino and carboxylic acid protecting groups (as well as means of formation and eventual deprotection), see T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, Second Edition, John Wiley & Sons, New York, 1991.
- Suitable leaving groups X 1 to X 5 for processes b) to d) are any leaving group known in the art for these types of reactions, for example halo, alkoxy, trifluoromethanesulfonyloxy, methanesulfonyloxy, or p-toluenesulfonyloxy; or a group (such as a hydroxy group) that may be converted into a leaving group (such as an oxytriphenylphosphonium group) in situ.
- Suitable values for R 1 containing a protected hydroxy group are any suitable protected hydroxy group known in the art, for example simple ethers such as a methyl ether, tert-butyl ether or silylethers such as —OSi[(1-4C)alkyl] 3 (wherein each (1-4C)alkyl group is independently selected from methyl, ethyl, propyl, isopropyl, and tertbutyl).
- Examples of such trialkylsilyl groups are trimethylsilyl, triethylsilyl, triisopropylsilyl and tert-butyldimethylsilyl.
- Compounds of Formula (XV) may be made by processes such as those shown in processes a) to d) and/or by those processes mentioned above for compounds of formulae (V) to (XIV).
- the pyrrolidone group in the compounds of formulae (V), (XI), (XII), (XIII), (XV) and (XVI) may be made by reaction of suitable precursors with compounds of formula (VII) or derivatives thereof, for example, by nucleophilic displacement of a leaving group X 1 in a compound of formula (VII).
- Compounds of formula (VII) are generally commercially available or maybe made by simple functional group interconversions from commercially available compounds, or by literature methods. Examples of approaches to the pyrrolidone group are outlined in Schemes 1 and 2 below and are further illustrated in the accompanying examples.
- Step (i) proceeds according to the Mitsunobu reaction as is well known in the literature, more specifically, step (i) involves the reaction of a compound of Formula (VIII) with 3-hydroxyoxolan-2-one in the presence of triphenyl phosphine and DIAD, in a suitable solvent, for example anhydrous THF, and at a suitable temperature, for example 0 to 25° C., more suitably 20 to 25° C.;
- a suitable solvent for example anhydrous THF
- Step (ii) involves the reaction of a compound of Formula (XVIII) with a suitable alcohol, for example ethanol, in the presence of a suitable base, for example potassium carbonate, and at a suitable temperature, for example 0 to 25° C., more suitably 20 to 25° C.;
- a suitable alcohol for example ethanol
- a suitable base for example potassium carbonate
- Step (iii) involves the reaction of a compound fo Formula (XIX) with methanesulfonyl chloride in the presence of a suitable base, for example triethylamine, in a suitable solvent, for example DCM, and at a suitable temperature, for example 0 to 25° C., more suitably 20 to 25° C.; and
- a suitable base for example triethylamine
- a suitable solvent for example DCM
- Steps (iv) and (v) involve the reaction of a compound of Formula (XX) with a suitable metal iodide, such as sodium iodide, and a (1-4C)alkylamine or (3-6C)cycloalkylamine, in a suitable solvent, for example acetonitrile, and at a suitable temperature with heating in a microwave, for example 100 to 130° C., more suitably 115 to 125° C.
- a suitable metal iodide such as sodium iodide
- a suitable solvent for example acetonitrile
- Step (i) involves the reaction of 2,4-dibromobutanoyl chloride with a (1-4C)alkylamine or (3-6C)cycloalkylamine in a suitable solvent, such as water and DCM, and at a suitable temperature, for example 0 to 50° C., more suitably 10 to 30° C.; and
- a suitable solvent such as water and DCM
- Step (ii) involves the reaction of a compound of Formula (XXIII) with a suitable base, for example sodium hydride, in a suitable solvent, for example THF, and at a suitable temperature, for example 0 to 30° C., more suitably 10 to 15° C.
- a suitable base for example sodium hydride
- THF a suitable solvent
- a suitable temperature for example 0 to 30° C., more suitably 10 to 15° C.
- substituents R 3 , R 6 and/or R 7 may be introduced into the molecule at any convenient point in the synthetic sequence or may be present in the starting materials.
- a precursor to one of these substituents may be present in the molecule during the process steps a) to e) above, and then be transformed into the desired substituent as a final step to form the compound of formula (I); followed where necessary by
- Ring C from a pre-cursor and form the phenoxy link in a one-pot reaction, so that it is unclear whether process c) or process e) is actually the final step.
- Rearrangement of Ring C may also occur in some circumstances, for example it may occur in the following circumstances:
- protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
- protecting groups are given below for the sake of convenience, in which “lower” signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned is of course within the scope of the invention.
- a carboxy protecting group may be the residue of an ester-forming aliphatic or araliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms).
- Examples of carboxy protecting groups include straight or branched chain (1-12C)alkyl groups (e.g. isopropyl, t-butyl); lower alkoxy lower alkyl groups (e.g. methoxymethyl, ethoxymethyl, isobutoxymethyl); lower aliphatic acyloxy lower alkyl groups, (e.g. acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl); lower alkoxycarbonyloxy lower alkyl groups (e.g.
- aryl lower alkyl groups e.g. p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, benzhydryl and phthalidyl
- tri(lower alkyl)silyl groups e.g. trimethylsilyl and t-butyldimethylsilyl
- tri(lower alkyl)silyl lower alkyl groups e.g. trimethylsilylethyl
- (2-6C)alkenyl groups e.g. allyl and vinylethyl
- Methods particularly appropriate for the removal of carboxyl protecting groups include for example acid-, metal- or enzymically-catalysed hydrolysis. Hydrogenation may also be used.
- hydroxy protecting groups include methyl, t-butyl, lower alkenyl groups (e.g. allyl); lower alkanoyl groups (e.g. acetyl); lower alkoxycarbonyl groups (e.g. t-butoxycarbonyl); lower alkenyloxycarbonyl groups (e.g. allyloxycarbonyl); aryl lower alkoxycarbonyl groups (e.g. benzoyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl); tri lower alkyl/arylsilyl groups (e.g.
- amino protecting groups include formyl, aralkyl groups (e.g. benzyl and substituted benzyl, e.g. p-methoxybenzyl, nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl); di-p-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (e.g.
- t-butoxycarbonyl lower alkenyloxycarbonyl (e.g. allyloxycarbonyl); aryl lower alkoxycarbonyl groups (e.g. benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl; trialkylsilyl (e.g. trimethylsilyl and t-butyldimethylsilyl); alkylidene (e.g. methylidene); benzylidene and substituted benzylidene groups.
- aryl lower alkoxycarbonyl groups e.g. benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl
- trialkylsilyl e.g. trimethylsilyl and t-butyldimethylsilyl
- Methods appropriate for removal of hydroxy and amino protecting groups include, for example, hydrogenation, nucleophilic displacement, acid-, base, metal- or enzymically-catalysed hydrolysis, catalytic hydrogenolysis or photolytically for groups such as o-nitrobenzyloxycarbonyl, or with fluoride ions for silyl groups.
- methylether protecting groups for hydroxy groups may be removed by trimethylsilyliodide.
- a tert-butyl ether protecting group for a hydroxy group may be removed by hydrolysis, for example by use of hydrochloric acid in methanol.
- protecting groups for amide groups include aralkoxymethyl (e.g. benzyloxymethyl and substituted benzyloxymethyl); alkoxymethyl (e.g. methoxymethyl and trimethylsilylethoxymethyl); tri alkyl/arylsilyl (e.g. trimethylsilyl, t-butyldimethylsily, t-butyldiphenylsilyl); tri alkyl/arylsilyloxymethyl (e.g. 1-butyldimethylsilyloxymethyl, t-butyldiphenylsilyloxymethyl); 4-alkoxyphenyl (e.g. 4-methoxyphenyl); 2,4-di(alkoxy)phenyl (e.g.
- 2,4-dimethoxyphenyl 4-alkoxybenzyl (e.g. 4-methoxybenzyl); 2,4-di(alkoxy)benzyl (e.g. 2,4-di(methoxy)benzyl); and alk-1-enyl (e.g. allyl, but-1-enyl and substituted vinyl e.g. 2-phenylvinyl).
- 4-alkoxybenzyl e.g. 4-methoxybenzyl
- 2,4-di(alkoxy)benzyl e.g. 2,4-di(methoxy)benzyl
- alk-1-enyl e.g. allyl, but-1-enyl and substituted vinyl e.g. 2-phenylvinyl
- Aralkoxymethyl, groups may be introduced onto the amide group by reacting the latter group with the appropriate aralkoxymethyl chloride, and removed by catalytic hydrogenation.
- Alkoxymethyl, tri alkyl/arylsilyl and tri alkyl/silyloxymethyl groups may be introduced by reacting the amide with the appropriate chloride and removing with acid; or in the case of the silyl containing groups, fluoride ions.
- the alkoxyphenyl and alkoxybenzyl groups are conveniently introduced by arylation or alkylation with an appropriate halide and removed by oxidation with ceric ammonium nitrate.
- alk-1-enyl groups may be introduced by reacting the amide with the appropriate aldehyde and removed with acid.
- CE001 column eluting with methanol at a flow rate of 50 mL/min; 420 mg of racemic material was separated in 3 injections of 15 mL at 11 mg/ml in 1:1:1 acetonitrile/ethanol/methanol to afford the product (179 mg, 32%) which eluted after its enantiomer.
- CE001 column eluting with methanol at a flow rate of 50 mL/min; 420 mg of racemic material was separated in 3 injections of 15 mL at 11 mg/ml in 1:1:1 acetonitrile/ethanol/methanol to afford the product (187 mg, 33%) which eluted before its enantiomer.
- N,N-Dimethylacetamide was removed by evaporation under reduced pressure.
- the residue was partitioned between ethyl acetate (30 mL) and water (50 mL).
- the organic phase was separated and the aqueous layer was acidified with hydrochloric acid (1N, 5 mL) and extracted with ethyl acetate (2 ⁇ 50 mL).
- the combined organic extracts were washed with brine, dried (MgSO 4 ) and concentrated under reduced pressure.
- the residue was purified by flash chromatography on silica eluting with 0-5% methanol in DCM to afford the product (120 mg, 40%).
- the N,N-dimethylacetamide was evaporated under reduced pressure and the residue was dissolved in water (20 mL) extracted with ethyl acetate (3 ⁇ 20 mL). The combined organic extracts were dried (MgSO 4 ) and evaporated. The residue was purified by flash chromatography on silica eluting with 0-5% methanol in DCM. The resulting compound was dissolved in ethyl acetate (110 mL), washed with citric acid (1N, 10 mL), water (10 mL) and brine (10 mL), dried (MgSO 4 ) and the solvent evaporated to afford the product (67 mg, 23%).
- the DMA was evaporated under reduced pressure and the residue was dissolved in water (200 mL), washed with ethyl acetate (3 ⁇ 50 mL), acidified with 2N hydrochloric acid and extracted with ethyl acetate (3 ⁇ 100 mL). The organic layer washed with water (2 ⁇ 20 mL) and brine (20 mL), dried (MgSO 4 ) and the solvent removed under reduced pressure to afford the product (6.18 g, 76%).
- 2,4-Dibromobutanoyl chloride (CAS no. 82820-87-9) (16.9 g, 64 mmol) in DCM (20 mL) was added dropwise to a solution of methylamine (20 mL) in water (30 mL) and DCM (30 mL) at 10-15° C., then warmed to 30° C. and stirred for 30 minutes. The organic layer was separated and the aqueous layer re-extracted with DCM (2 ⁇ 10 mL), the combined organic layers were washed with brine (20 mL), dried (MgSO 4 ) and evaporated to afford the product (16.3 g, 98%).
- Methyl 3-hydroxy-5-phenylmethoxy-benzoate (CAS no. 54915-31-0) (10.3 g, 40 mmol) and 3-bromo-1-methyl-pyrrolidin-2-one (Intermediate 4) (8.54 g, 48 mmol) were dissolved in DMF, treated with potassium carbonate (12.1 g, 88 mmol) and stirred at room temperature for 16 hours and then at 50° C. for 3 hours. The DMF was evaporated under reduced pressure and the residue partitioned between ethyl acetate (100 mL) and water (30 mL). The organic layer was separated, washed with brine (30 mL), dried (MgSO 4 ) and evaporated under reduced pressure.
- the residue was purified by flash chromatography on silica eluting with 0-100% ethyl acetate in hexane to give the racemic product (8.7 g).
- the desired product was separated from its enantiomer by chiral HPLC using Merck 50 mm 20 ⁇ m Chiralpak AS—No ASV00SC JG001 and ASV000SC BD004 columns in series, eluting with 30% ethylacetate in isohexane at a flow rate of 60 mL/min, using 9 separate injections of 70 mL of a 14 mg/ml solution of the racemate in ethanol (32 mL) and isohexane (38 mL) to afford the product (3.6 g, 41%) which eluted before its enantiomer.
- Methyl 3-hydroxy-5-phenylmethoxy-benzoate (CAS no. 54915-31-0) (10.3 g, 40 mmol) and 3-bromo-1-methyl-pyrrolidin-2-one (Intermediate 4) (8.54 g, 48 mmol) were dissolved in DMF and treated with potassium carbonate (12.1 g, 88 mmol) and stirred at room temperature for 16 hours and then at 50° C. for 3 hours. The DMF was evaporated under reduced pressure and the residue partitioned between ethyl acetate (100 mL) and water (30 mL). The organic layer was separated, washed with brine (30 mL), dried (MgSO 4 ) and evaporated under reduced pressure.
- the residue was purified by flash chromatography on silica eluting with 0-100% ethyl acetate in hexane to give the racemic product (8.7 g).
- the desired product was separated from its enantiomer by chiral HPLC using Merck 50 mm 20 ⁇ m Chiralpak AS—No ASV00SC JG001 and ASV000SC BD004 columns in series, eluting with 30% ethylacetate in isohexane at a flow rate of 60 mL/min, using 9 separate injections of 70 mL of a 14 mg/ml solution of the racemate in Ethanol (32 mL) and isohexane (38 mL) to afford the product (3.6 g, 41%) which eluted after its enantiomer.
- 5,6-Dichloropyridine-3-carboxylic acid (CAS no. 41667-95-2) (32 g, 0.17 mol) was suspended in DCM (500 mL) and 1M HCl in ether (0.17 L, 0.17 mol) added. Oxalyl chloride (17 mL, 0.20 mol) and then DMF (2 drops) were added and stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, azeotroped with toluene and re-dissolved into DCM (250 mL). Azetidine hydrochloride (17.5 g, 0.18 mol) was added, followed by triethylamine (51 mL, 0.37 mol) and the reaction stirred at room temperature for 2 hours.
- the reaction mixture was concentrated under reduced pressure then water (500 mL) and ethyl acetate (500 mL) were added. The organic layer was separated and the aqueous phase was re-extracted with ethyl acetate (5 ⁇ 150 mL). The combined organics were washed with citric acid (250 mL), saturated sodium bicarbonate solution (250 mL), brine (250 mL), dried (MgSO 4 ), filtered and evaporated under reduced pressure to give a solid which was recrystallised in ethyl acetate and dried under reduced pressure to give the product (18.2 g, 47%).
- Methanesulfonyl chloride 13 L, 0.16 mmol
- triethylamine 34 ⁇ L, 0.24 mmol
- ethyl 2-[3-[6-(azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(5-methylpyrazin-2-yl)carbamoyl]phenoxy]-4-hydroxy-butanoate (Intermediate 28) (65 mg, 0.12 mmol) in DCM (5 mL) at 0° C. under nitrogen. The reaction was allowed to warm to RT and stirred for 2 hours.
- the DMA was evaporated under reduced pressure and the residue was dissolved in water (520 mL) washed with ethyl acetate (3 ⁇ 20 mL).
- the aqueous fraction was acidified with 2N hydrochloric acid and extracted with ethyl acetate (3 ⁇ 100 mL), the combined organic layers were washed with water (2 ⁇ 20 mL) and brine (20 mL), dried (MgSO 4 ) and the solvent removed under reduced pressure.
- the residue was dissolved in THF (6 mL) and methanol (3 mL) and was treated dropwise with 2M (trimethylsilyl)diazomethane in hexane (1.1 mL).
- Azetidine hydrochloride (6.14 g, 65.5 mmol) then triethylamine (24 mL, 187 mmol) were added and the mixture stirred at ambient temperature for 20 hours.
- the mixture was concentrated under reduced pressure and ethyl acetate (400 mL) added to the residue.
- the resulting mixture was washed with water (100 mL), filtered, washed with 1M citric acid solution (50 mL), saturated sodium bicarbonate solution (50 mL) and brine (50 mL), dried (MgSO 4 ), filtered and the solvent removed under reduced pressure.
- the organic phase was separated, washed with water (10 mL) and brine (20 mL), dried (MgSO 4 ) and evaporated.
- the aqueous phase was acidified to pH 1 with 2N hydrochloric acid extracted with ethyl acetate (2 ⁇ 30 mL).
- the combined organic extracts were washed with water (2 ⁇ 20 mL), brine (20 mL), dried (MgSO 4 ) and evaporated.
- the residue was dissolved in THF (2 mL) and methanol (1 mL) and treated with 2M TMS-diazomethane (0.14 mL) stirred for 30 minutes.
- Enzymatic activity of recombinant human pancreatic GLK may be measured by incubating GLK, ATP and glucose.
- the rate of product formation may be determined by coupling the assay to a G-6-P dehydrogenase, NADP/NADPH system and measuring the linear increase with time of optical density at 340 nm (Brocklehurst et al (Diabetes 2004, 53, 535-541).
- Activation of GLK by compounds can be assessed using this assay in the presence or absence of GLKRP as described in Brocklehurst et al (Diabetes 2004, 53, 535-541).
- GKH1 and GKH4 were used to test the compounds of the invention.
- the GKH1 assay is a manual, bench-top rate assay using 60 nmol/l of recombinant human pancreatic GLK.
- the GLK activity rate is measured over a 5 minute window using a Multiskan Ascent spectrophotometer.
- the GKH4 assay is an automated end-point assay using 10 nmol/l of recombinant human pancreatic GLK.
- the GLK activity is measured at 10 minutes after the initiation of the assay on a Perkin Elmer Envision spectrophotometer.
- GKH1 and GKH4 do not contain GLKRP.
- Compounds of the invention generally have an activating activity for glucokinase with an EC 50 of less than about 20 ⁇ M, such as less than about 5 ⁇ M, such as less than about 1 ⁇ M, such as less than 500 nM, such as less than about 100 nM.
- Examples 1 to 32 activated glucokinase in the GKH1 and/or GHK4 variants of the assay with EC 50 values as shown below.
- GKH1 EC 50 Value ( ⁇ M) GKH4 EC 50 Value ( ⁇ M) 1 0.09 0.30 2 3.93 3 0.29 4 18.31 5 0.15 6 0.19 7 0.57 8 0.19 9 0.12 10 0.26 11 0.14 0.31 12 0.30 0.43 13 0.43 0.17 14 0.08 15 0.10 0.35 16 0.31 17 0.60 18 3.34 7.23 19 0.59 20 0.42 0.90 21 0.21 1.11 22 2.37 6.61 23 0.05 0.22 24 0.15 0.57 25 0.03 0.04 26 0.39 27 0.66 28 0.57 29 0.10 30 0.06 31 1.08 32 0.06 Production of Recombinant GLK and GLKRP:
- Human GLK and GLKRP cDNA was obtained by PCR from human pancreatic and hepatic mRNA respectively, using established techniques described in Sambrook J, Fritsch EF & Maniatis T, 1989. PCR primers were designed according to the GLK and GLKRP cDNA sequences shown in Tanizawa et al., Proc Natl Acad Sci 1991 Aug. 15; 88(16):7294-7 1991 and Bonthron, D. T. et al 1994 (later corrected in and Warner, J. P. et al., Mamm Genome. 1995 August; 6(8):532-61995).
- GLK and GLKRP cDNA was cloned in E. coli using pBluescript II.
- E. Coli transformations were generally carried out by electroporation. 400 mL cultures of strains DH5a or BL21(DE3) were grown in L-broth to an OD 600 of 0.5 and harvested by centrifugation at 2,000 g. The cells were washed twice in ice-cold deionised water, resuspended in 1 mL 10% glycerol and stored in aliquots at ⁇ 70° C. Ligation mixes were desalted using Millipore V SeriesTM membranes (0.0025 mm) pore size).
- GLK was expressed from the vector pTB375NBSE in E. coli BL21 cells, producing a recombinant protein containing a 6-His tag immediately adjacent to the N-terminal methionine.
- another suitable vector is pET21 (+)DNA, Novagen, Cat number 697703.
- the 6-His tag was used to allow purification of the recombinant protein on a column packed with nickel-nitrilotriacetic acid agarose purchased from Qiagen (cat no 30250).
- GLKRP was expressed from the vector pFLAG CTC (IBI Kodak) in E. coli BL21 cells, producing a recombinant protein containing a C-terminal FLAG tag.
- the protein was purified initially by DEAE Sepharose ion exchange followed by utilisation of the FLAG tag for final purification on an M2 anti-FLAG immunoaffinity column purchased from Sigma-Aldrich (cat no. A1205).
- Oral glucose tolerance tests may be performed on conscious Zucker obese fa/fa rats (age 12-13 weeks or older) fed a high fat diet (45% kcal fat) for at least two weeks prior to experimentation. The animals are fasted for 2 hours before use for experiments. A test compound or a vehicle is given orally 120 minutes before oral administration of a glucose solution at a dose of 2 g/kg body weight. Blood glucose levels are measured using a Accucheck glucometer from tail bled samples taken at different time points before and after administration of glucose (time course of 60 minutes).
- a time curve of the blood glucose levels is generated and the area-under-the-curve (AUC) for 120 minutes calculated (the time of glucose administration being time zero). Percent reduction in glucose excursion is determined using the AUC in the vehicle-control group as zero percent reduction. 3) Glucokinase Activator Efficacy in Free Feeding Obese Male Zucker Fatty Rats
- the glucose lowering efficacy of a glucokinase was assessed by measuring free feeding blood glucose levels in obese male Zucker fatty rats as follows. Rats were received from the AstraZeneca breeding unit at 9 weeks of age and allowed to acclimatise to a reverse light cycle (0900-2100 dark phase) for 3 weeks. On the study day the animals were split into two groups: vehicle group contains 10 animals and a single test group contains 8 animals; for each additional test group the control group size was increased by 2 animals.
- Animals were orally dosed, at a volume of 5 ml/kg, at 0800 (ie 1h prior to entering the dark phase) with vehicle (1% w/v Pluronic F127) or the test compound (formulated in 1% Pluronic F127) at 3 mg/kg.
- Blood glucose was measured from a 10 ⁇ l needle prick sample from the tail vein and determined using a Roche Accu-chek monitor. Measurements were taken at time zero (ie immediately prior to dosing), 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h and 24 h thereafter. Samples at the 12 h and 24 h time points were only taken if sufficient efficacy had been observed at the 8 hour time point.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/876,370 US7902200B2 (en) | 2006-10-23 | 2007-10-22 | Chemical compounds |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86249306P | 2006-10-23 | 2006-10-23 | |
US89199307P | 2007-02-28 | 2007-02-28 | |
US11/876,370 US7902200B2 (en) | 2006-10-23 | 2007-10-22 | Chemical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080171734A1 US20080171734A1 (en) | 2008-07-17 |
US7902200B2 true US7902200B2 (en) | 2011-03-08 |
Family
ID=39324963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/876,370 Expired - Fee Related US7902200B2 (en) | 2006-10-23 | 2007-10-22 | Chemical compounds |
Country Status (18)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100093757A1 (en) * | 2008-08-04 | 2010-04-15 | Astrazeneca Ab | Therapeutic agents 414 |
US20100210621A1 (en) * | 2009-02-13 | 2010-08-19 | Astrazeneca Ab | Crystalline polymorphic form 631 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005214132B9 (en) * | 2004-02-18 | 2009-06-25 | Astrazeneca Ab | Benzamide derivatives and their use as glucokinae activating agents |
TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
NZ575513A (en) * | 2005-07-09 | 2009-11-27 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
SA07280576B1 (ar) * | 2006-10-26 | 2011-06-22 | استرازينيكا ايه بي | مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
WO2010116176A1 (en) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity |
WO2010116177A1 (en) | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity |
US8450494B2 (en) | 2009-06-22 | 2013-05-28 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (GK) activators |
CA2768232A1 (en) | 2009-07-31 | 2011-02-03 | Cadila Healthcare Limited | Substituted benzamide derivatives as glucokinase (gk) activators |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP3294726A1 (en) | 2015-04-17 | 2018-03-21 | AbbVie Inc. | Indazolones as modulators of tnf signaling |
GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
Citations (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2750393A (en) | 1954-12-01 | 1956-06-12 | Sterling Drug Inc | Iodinated 5-henzamidotetrazoles and preparation thereof |
US2967194A (en) | 1958-05-15 | 1961-01-03 | Pennsalt Chemicals Corp | 4-trifluoromethylsalicylamides |
FR1526074A (fr) | 1967-03-22 | 1968-05-24 | Rech S Ind S O R I Soc D | Méthoxy-phényl-amino-2-thiazoles, leurs amides et leurs procédés de préparation |
FR2088019A1 (en) | 1970-05-08 | 1972-01-07 | Rabot Ets David | Esters of 2 and 6-substituted nicotinic acids - with vasomotor active |
GB1352415A (en) | 1970-05-03 | 1974-05-08 | Boots Co Ltd | Esters of substituted nicotine acids |
JPS50105559A (US07902200-20110308-C00103.png) | 1973-12-22 | 1975-08-20 | ||
US3917625A (en) | 1972-12-06 | 1975-11-04 | Smith Kline French Lab | Salicylamides and compositions thereof |
US3950351A (en) | 1973-08-08 | 1976-04-13 | S.P.R.L. Phavic | New derivatives of 2-benzamido-5-nitro thiazoles |
US4009174A (en) | 1972-12-08 | 1977-02-22 | The Boots Company Limited | Esters of substituted nicotinic acids |
CS173097B1 (US07902200-20110308-C00103.png) | 1972-12-01 | 1977-02-28 | ||
US4105785A (en) | 1976-03-17 | 1978-08-08 | Centre Europeen De Recherches Mauvernay | Anti-depressive 2-methyl-4-[(3'-dimethylamino)propylidine]-9,10-dihydrobenzo [4,5]cyclohepta[1,2b]furan compounds |
US4146631A (en) | 1976-11-05 | 1979-03-27 | May & Baker Limited | Benzamide derivatives |
GB1588242A (en) | 1977-10-28 | 1981-04-23 | May & Baker Ltd | N-(tetrazol-5-yl)-salicylamide derivatives |
JPS5721320A (en) | 1980-07-11 | 1982-02-04 | Chugai Pharmaceut Co Ltd | Blood sugar level depressing agent |
JPS5775962A (en) | 1980-10-29 | 1982-05-12 | Shionogi & Co Ltd | 2-alkoxybenzamide derivative |
JPS5869812A (ja) | 1981-10-22 | 1983-04-26 | Chugai Pharmaceut Co Ltd | 血糖降下剤 |
US4434170A (en) | 1980-11-07 | 1984-02-28 | Delalande S.A. | Nor-tropane derivatives, and their application in therapeutics |
US4474792A (en) | 1979-06-18 | 1984-10-02 | Riker Laboratories, Inc. | N-Tetrazolyl benzamides and anti-allergic use thereof |
JPS61205937A (ja) | 1985-03-09 | 1986-09-12 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀カラ−写真感光材料 |
US4634783A (en) | 1983-01-28 | 1987-01-06 | Torii & Co. Ltd. | Novel amidine compound |
EP0219436A2 (en) | 1985-10-16 | 1987-04-22 | Mitsubishi Kasei Corporation | Thiazole derivative and leukotriene antagonist containing the same as the effective ingredients |
JPS62158252A (ja) | 1985-12-28 | 1987-07-14 | Kirin Brewery Co Ltd | 4−アミノピリジンベンズアミド誘導体 |
EP0316704A2 (de) | 1987-11-17 | 1989-05-24 | F. Hoffmann-La Roche Ag | Fluorcytidinderivate, deren Herstellung und Arzneimittel, die diese Derivate enthalten |
GB2216517A (en) | 1988-03-03 | 1989-10-11 | Toyama Chemical Co Ltd | 1-(3-aryl-prop-2-enyl)-4-tricyclyl-piperazines |
EP0353452A1 (de) | 1988-07-02 | 1990-02-07 | Henkel Kommanditgesellschaft auf Aktien | Oxidationshaarfärbemittel |
JPH04300874A (ja) | 1991-03-29 | 1992-10-23 | Tsumura & Co | 新規2,4−ジアミノ−1,3,5−トリアジン誘導体 |
JPH04300832A (ja) | 1991-03-29 | 1992-10-23 | Tsumura & Co | 2,4−ジアミノ−1,3,5−トリアジン誘導体を有 効成分とするロイコトリエン拮抗剤 |
US5258407A (en) | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5273986A (en) | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
JPH0627025A (ja) | 1992-07-06 | 1994-02-04 | Toto Ltd | 分子認識機能膜及びこれを用いたセンサー |
EP0619116A2 (en) | 1993-04-05 | 1994-10-12 | Hoechst Japan Limited | Use of synthetic retinoids for osteopathy |
EP0620216A1 (en) | 1993-04-13 | 1994-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives and their use as vasopressin antagonists |
US5466715A (en) | 1991-12-31 | 1995-11-14 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5510478A (en) | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
JPH08143565A (ja) | 1994-11-16 | 1996-06-04 | Fujisawa Pharmaceut Co Ltd | ベンズアミド化合物 |
JPH08173525A (ja) | 1994-09-01 | 1996-07-09 | Leland L Ladd | 医療用灌注ポンプ及びシステム |
JPH08301760A (ja) | 1995-05-10 | 1996-11-19 | Shiseido Co Ltd | 皮膚外用剤 |
JPH0940557A (ja) | 1995-05-25 | 1997-02-10 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
JPH09202786A (ja) | 1995-11-24 | 1997-08-05 | Otsuka Pharmaceut Factory Inc | 縮環ピリミジン誘導体 |
US5661153A (en) | 1994-07-19 | 1997-08-26 | Japan Energy Corporation | 1-arylpyrimidine derivatives and pharmaceutical use thereof |
US5672750A (en) | 1994-12-16 | 1997-09-30 | Eastman Chemical Company | Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride |
US5712270A (en) | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
JPH10101672A (ja) | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
JPH10101671A (ja) | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
JPH10212271A (ja) | 1997-01-31 | 1998-08-11 | Zeria Pharmaceut Co Ltd | N−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体 |
US5849735A (en) | 1995-01-17 | 1998-12-15 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
JPH1129480A (ja) | 1997-05-12 | 1999-02-02 | Otsuka Pharmaceut Factory Inc | 縮環ピリミジン誘導体を含有する医薬組成物 |
GB2331748A (en) | 1997-11-28 | 1999-06-02 | Zeneca Ltd | Insecticidal thiazole derivatives |
JP2000086657A (ja) | 1998-09-10 | 2000-03-28 | Teikoku Hormone Mfg Co Ltd | 5−アミノイソキサゾール誘導体 |
US6110945A (en) | 1998-06-03 | 2000-08-29 | Celltech Therapeutics Limited | Aromatic amine derivatives |
EP1048659A1 (en) | 1997-11-12 | 2000-11-02 | Institute of Medicinal Molecular Design, Inc. | Retinoid receptor agonists |
US6197798B1 (en) | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
US6200995B1 (en) | 1998-01-29 | 2001-03-13 | Tularik Inc. | PPAR-γ modulators |
US6207693B1 (en) | 1996-12-02 | 2001-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives having a vasopressin antagonistic activity |
US6214878B1 (en) | 1996-12-31 | 2001-04-10 | Galderma Research & Development S.N.C. | Stilbene compounds comprising an adamantyl group, compositions and methods thereof |
US6242474B1 (en) | 1997-06-27 | 2001-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Aromatic ring derivatives |
US6255335B1 (en) | 1998-04-16 | 2001-07-03 | Bayer Aktiengesellschaft | Substituted 2-oxo-alkanoic acid-[2-(indol-3-yl)-ethyl] amides |
EP1132381A1 (en) | 2000-03-08 | 2001-09-12 | Cermol S.A. | Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them |
US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
US20020002183A1 (en) | 2000-02-29 | 2002-01-03 | Bing-Yan Zhu | Benzamides and related inhibitors of factor Xa |
US6348474B1 (en) | 1997-06-27 | 2002-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonamide compounds and medicinal use thereof |
US6388071B2 (en) | 2000-05-03 | 2002-05-14 | Hoffmann-La Roche Inc. | Alkynyl phenyl heteroaromatic glucokinase activators |
US20020095044A1 (en) | 2000-04-06 | 2002-07-18 | Prakash Jagtap | Inhibitors of inflammation and reperfusion injury and methods of use thereof |
US6448399B1 (en) | 2000-12-06 | 2002-09-10 | Hoffmann-La Roche Inc. | Fused heteroaromatic glucokinase activators |
US6486349B1 (en) | 1999-11-18 | 2002-11-26 | Centaur Pharmaceuticals, Inc. | Amide therapeutics and methods for treating inflammatory bowel disease |
US6528543B1 (en) | 1999-03-29 | 2003-03-04 | Hoffman-La Roche Inc. | Urea derivatives |
GB2385328A (en) | 2001-12-19 | 2003-08-20 | Hoffmann La Roche | Crystals of glucokinase and methods of growing them |
EP1336607A1 (en) | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
EP1357116A1 (en) | 2001-02-02 | 2003-10-29 | Yamanouchi Pharmaceutical Co. Ltd. | 2-acylaminothiazole derivative or its salt |
EP1400540A2 (en) | 1997-08-27 | 2004-03-24 | E.I. Du Pont De Nemours And Company | Process for the polymerization of olefins |
US20040077555A1 (en) | 2000-11-22 | 2004-04-22 | Tsukasa Ishihara | Substituted benzene derivatives or salts thereof |
EP1496052A1 (en) | 2002-03-26 | 2005-01-12 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
US20050080106A1 (en) | 2001-08-17 | 2005-04-14 | Astrazeneca Ab | Compounds effecting glucokinase |
US20050148605A1 (en) | 2003-11-13 | 2005-07-07 | Ambit Biosciences Corporation | Amide derivatives as ABL modulators |
EP1600442A1 (en) | 2003-02-26 | 2005-11-30 | Banyu Pharmaceutical Co., Ltd. | Heteroarylcarbamoylbenzene derivative |
US20060004010A1 (en) | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
EP1702919A1 (en) | 2003-12-29 | 2006-09-20 | Banyu Pharmaceutical Co., Ltd. | Novel 2-heteroaryl-substituted benzimidazole derivative |
CA2605738A1 (en) | 2005-04-25 | 2006-11-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Novel azaheterocyclic compounds as kinase inhibitors |
US7132546B2 (en) | 2000-12-22 | 2006-11-07 | Ishihara Sangyo Kaisha, Ltd. | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
US20060258728A1 (en) | 2001-08-09 | 2006-11-16 | Kousuke Tani | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
US7199140B2 (en) | 2001-06-26 | 2007-04-03 | Astrazeneca Ab | Vinyl phenyl derivatives as GLK activators |
US20070078168A1 (en) | 2003-10-31 | 2007-04-05 | Caulkett Peter W R | Pyridine carboxylic acid derivatives as glucokinase modulators |
US7230108B2 (en) | 2002-11-19 | 2007-06-12 | Astrazeneca Ab | Quinoline derivatives as glucokinase ligands |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
US20110059941A1 (en) * | 2005-05-24 | 2011-03-10 | Peter William Rodney Caulkett | 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators |
NZ575513A (en) * | 2005-07-09 | 2009-11-27 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
WO2007017649A1 (en) * | 2005-08-09 | 2007-02-15 | Astrazeneca Ab | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes |
JP2009513711A (ja) * | 2005-11-01 | 2009-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グルコキナーゼのアロステリックモジュレーターとしての置換ピロロン |
-
2007
- 2007-10-19 TW TW096139393A patent/TW200825063A/zh unknown
- 2007-10-22 PE PE2007001425A patent/PE20081467A1/es not_active Application Discontinuation
- 2007-10-22 JP JP2009533935A patent/JP2010507640A/ja not_active Withdrawn
- 2007-10-22 RU RU2009114982/04A patent/RU2009114982A/ru not_active Application Discontinuation
- 2007-10-22 CA CA002667435A patent/CA2667435A1/en not_active Abandoned
- 2007-10-22 KR KR1020097010059A patent/KR20090068289A/ko not_active Application Discontinuation
- 2007-10-22 WO PCT/GB2007/004018 patent/WO2008050101A2/en active Application Filing
- 2007-10-22 EP EP07824267A patent/EP2086964A2/en not_active Withdrawn
- 2007-10-22 CL CL200703033A patent/CL2007003033A1/es unknown
- 2007-10-22 US US11/876,370 patent/US7902200B2/en not_active Expired - Fee Related
- 2007-10-22 MX MX2009004362A patent/MX2009004362A/es not_active Application Discontinuation
- 2007-10-22 BR BRPI0718504-9A patent/BRPI0718504A2/pt not_active Application Discontinuation
- 2007-10-22 AU AU2007310608A patent/AU2007310608A1/en not_active Abandoned
- 2007-10-22 AR ARP070104658A patent/AR063499A1/es unknown
- 2007-10-29 UY UY30660A patent/UY30660A1/es unknown
-
2009
- 2009-04-16 IL IL198142A patent/IL198142A0/en unknown
- 2009-04-20 CO CO09039732A patent/CO6160318A2/es unknown
- 2009-04-22 NO NO20091599A patent/NO20091599L/no not_active Application Discontinuation
Patent Citations (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2750393A (en) | 1954-12-01 | 1956-06-12 | Sterling Drug Inc | Iodinated 5-henzamidotetrazoles and preparation thereof |
US2967194A (en) | 1958-05-15 | 1961-01-03 | Pennsalt Chemicals Corp | 4-trifluoromethylsalicylamides |
FR1526074A (fr) | 1967-03-22 | 1968-05-24 | Rech S Ind S O R I Soc D | Méthoxy-phényl-amino-2-thiazoles, leurs amides et leurs procédés de préparation |
GB1352415A (en) | 1970-05-03 | 1974-05-08 | Boots Co Ltd | Esters of substituted nicotine acids |
FR2088019A1 (en) | 1970-05-08 | 1972-01-07 | Rabot Ets David | Esters of 2 and 6-substituted nicotinic acids - with vasomotor active |
CS173097B1 (US07902200-20110308-C00103.png) | 1972-12-01 | 1977-02-28 | ||
US3917625A (en) | 1972-12-06 | 1975-11-04 | Smith Kline French Lab | Salicylamides and compositions thereof |
US4009174A (en) | 1972-12-08 | 1977-02-22 | The Boots Company Limited | Esters of substituted nicotinic acids |
US3950351A (en) | 1973-08-08 | 1976-04-13 | S.P.R.L. Phavic | New derivatives of 2-benzamido-5-nitro thiazoles |
JPS50105559A (US07902200-20110308-C00103.png) | 1973-12-22 | 1975-08-20 | ||
US4105785A (en) | 1976-03-17 | 1978-08-08 | Centre Europeen De Recherches Mauvernay | Anti-depressive 2-methyl-4-[(3'-dimethylamino)propylidine]-9,10-dihydrobenzo [4,5]cyclohepta[1,2b]furan compounds |
GB1561350A (en) | 1976-11-05 | 1980-02-20 | May & Baker Ltd | Benzamide derivatives |
US4146631A (en) | 1976-11-05 | 1979-03-27 | May & Baker Limited | Benzamide derivatives |
GB1588242A (en) | 1977-10-28 | 1981-04-23 | May & Baker Ltd | N-(tetrazol-5-yl)-salicylamide derivatives |
US4474792A (en) | 1979-06-18 | 1984-10-02 | Riker Laboratories, Inc. | N-Tetrazolyl benzamides and anti-allergic use thereof |
JPS5721320A (en) | 1980-07-11 | 1982-02-04 | Chugai Pharmaceut Co Ltd | Blood sugar level depressing agent |
JPS5775962A (en) | 1980-10-29 | 1982-05-12 | Shionogi & Co Ltd | 2-alkoxybenzamide derivative |
US4434170A (en) | 1980-11-07 | 1984-02-28 | Delalande S.A. | Nor-tropane derivatives, and their application in therapeutics |
JPS5869812A (ja) | 1981-10-22 | 1983-04-26 | Chugai Pharmaceut Co Ltd | 血糖降下剤 |
US4634783A (en) | 1983-01-28 | 1987-01-06 | Torii & Co. Ltd. | Novel amidine compound |
JPS61205937A (ja) | 1985-03-09 | 1986-09-12 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀カラ−写真感光材料 |
EP0219436A2 (en) | 1985-10-16 | 1987-04-22 | Mitsubishi Kasei Corporation | Thiazole derivative and leukotriene antagonist containing the same as the effective ingredients |
JPS62158252A (ja) | 1985-12-28 | 1987-07-14 | Kirin Brewery Co Ltd | 4−アミノピリジンベンズアミド誘導体 |
EP0316704A2 (de) | 1987-11-17 | 1989-05-24 | F. Hoffmann-La Roche Ag | Fluorcytidinderivate, deren Herstellung und Arzneimittel, die diese Derivate enthalten |
US4966891A (en) | 1987-11-17 | 1990-10-30 | Hoffmann-La Roche Inc. | Fluorocytidine derivatives |
GB2216517A (en) | 1988-03-03 | 1989-10-11 | Toyama Chemical Co Ltd | 1-(3-aryl-prop-2-enyl)-4-tricyclyl-piperazines |
EP0353452A1 (de) | 1988-07-02 | 1990-02-07 | Henkel Kommanditgesellschaft auf Aktien | Oxidationshaarfärbemittel |
JPH04300832A (ja) | 1991-03-29 | 1992-10-23 | Tsumura & Co | 2,4−ジアミノ−1,3,5−トリアジン誘導体を有 効成分とするロイコトリエン拮抗剤 |
JPH04300874A (ja) | 1991-03-29 | 1992-10-23 | Tsumura & Co | 新規2,4−ジアミノ−1,3,5−トリアジン誘導体 |
US5258407A (en) | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5466715A (en) | 1991-12-31 | 1995-11-14 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5273986A (en) | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
US5399702A (en) | 1992-07-02 | 1995-03-21 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
JPH0627025A (ja) | 1992-07-06 | 1994-02-04 | Toto Ltd | 分子認識機能膜及びこれを用いたセンサー |
EP0619116A2 (en) | 1993-04-05 | 1994-10-12 | Hoechst Japan Limited | Use of synthetic retinoids for osteopathy |
EP0620216A1 (en) | 1993-04-13 | 1994-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives and their use as vasopressin antagonists |
US5661153A (en) | 1994-07-19 | 1997-08-26 | Japan Energy Corporation | 1-arylpyrimidine derivatives and pharmaceutical use thereof |
JPH08173525A (ja) | 1994-09-01 | 1996-07-09 | Leland L Ladd | 医療用灌注ポンプ及びシステム |
JPH08143565A (ja) | 1994-11-16 | 1996-06-04 | Fujisawa Pharmaceut Co Ltd | ベンズアミド化合物 |
US5510478A (en) | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
US5672750A (en) | 1994-12-16 | 1997-09-30 | Eastman Chemical Company | Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride |
US5849735A (en) | 1995-01-17 | 1998-12-15 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
JPH08301760A (ja) | 1995-05-10 | 1996-11-19 | Shiseido Co Ltd | 皮膚外用剤 |
JPH0940557A (ja) | 1995-05-25 | 1997-02-10 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
US5712270A (en) | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
JPH09202786A (ja) | 1995-11-24 | 1997-08-05 | Otsuka Pharmaceut Factory Inc | 縮環ピリミジン誘導体 |
JPH10101672A (ja) | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
JPH10101671A (ja) | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
US6316482B1 (en) | 1996-12-02 | 2001-11-13 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives having a vasopressin antagonistic activity |
US6207693B1 (en) | 1996-12-02 | 2001-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives having a vasopressin antagonistic activity |
US6214878B1 (en) | 1996-12-31 | 2001-04-10 | Galderma Research & Development S.N.C. | Stilbene compounds comprising an adamantyl group, compositions and methods thereof |
JPH10212271A (ja) | 1997-01-31 | 1998-08-11 | Zeria Pharmaceut Co Ltd | N−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体 |
JPH1129480A (ja) | 1997-05-12 | 1999-02-02 | Otsuka Pharmaceut Factory Inc | 縮環ピリミジン誘導体を含有する医薬組成物 |
US6242474B1 (en) | 1997-06-27 | 2001-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Aromatic ring derivatives |
US6348474B1 (en) | 1997-06-27 | 2002-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonamide compounds and medicinal use thereof |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
EP1400540A2 (en) | 1997-08-27 | 2004-03-24 | E.I. Du Pont De Nemours And Company | Process for the polymerization of olefins |
EP1048659A1 (en) | 1997-11-12 | 2000-11-02 | Institute of Medicinal Molecular Design, Inc. | Retinoid receptor agonists |
GB2331748A (en) | 1997-11-28 | 1999-06-02 | Zeneca Ltd | Insecticidal thiazole derivatives |
US20010027200A1 (en) | 1998-01-29 | 2001-10-04 | Tularik Inc. | PPARgamma modulators |
US6200995B1 (en) | 1998-01-29 | 2001-03-13 | Tularik Inc. | PPAR-γ modulators |
US6255335B1 (en) | 1998-04-16 | 2001-07-03 | Bayer Aktiengesellschaft | Substituted 2-oxo-alkanoic acid-[2-(indol-3-yl)-ethyl] amides |
US6110945A (en) | 1998-06-03 | 2000-08-29 | Celltech Therapeutics Limited | Aromatic amine derivatives |
US6369229B1 (en) | 1998-06-03 | 2002-04-09 | Celltech Therapeutics, Limited | Pyridylalanine derivatives |
US6197798B1 (en) | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
JP2000086657A (ja) | 1998-09-10 | 2000-03-28 | Teikoku Hormone Mfg Co Ltd | 5−アミノイソキサゾール誘導体 |
US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
US6528543B1 (en) | 1999-03-29 | 2003-03-04 | Hoffman-La Roche Inc. | Urea derivatives |
US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
US20040014968A1 (en) | 1999-03-29 | 2004-01-22 | Bizzarro Fred Thomas | Heteroaromatic glucokinase activators |
US6486349B1 (en) | 1999-11-18 | 2002-11-26 | Centaur Pharmaceuticals, Inc. | Amide therapeutics and methods for treating inflammatory bowel disease |
US6376515B2 (en) | 2000-02-29 | 2002-04-23 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor Xa |
US20020002183A1 (en) | 2000-02-29 | 2002-01-03 | Bing-Yan Zhu | Benzamides and related inhibitors of factor Xa |
US20030162690A1 (en) | 2000-02-29 | 2003-08-28 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor Xa |
EP1132381A1 (en) | 2000-03-08 | 2001-09-12 | Cermol S.A. | Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them |
US20020095044A1 (en) | 2000-04-06 | 2002-07-18 | Prakash Jagtap | Inhibitors of inflammation and reperfusion injury and methods of use thereof |
US6388071B2 (en) | 2000-05-03 | 2002-05-14 | Hoffmann-La Roche Inc. | Alkynyl phenyl heteroaromatic glucokinase activators |
US20040077555A1 (en) | 2000-11-22 | 2004-04-22 | Tsukasa Ishihara | Substituted benzene derivatives or salts thereof |
US6545155B2 (en) | 2000-12-06 | 2003-04-08 | Hoffmann-La Roche Inc. | Fused heteroaromatic glucokinase activators |
US6448399B1 (en) | 2000-12-06 | 2002-09-10 | Hoffmann-La Roche Inc. | Fused heteroaromatic glucokinase activators |
US7132546B2 (en) | 2000-12-22 | 2006-11-07 | Ishihara Sangyo Kaisha, Ltd. | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
EP1357116A1 (en) | 2001-02-02 | 2003-10-29 | Yamanouchi Pharmaceutical Co. Ltd. | 2-acylaminothiazole derivative or its salt |
US7199140B2 (en) | 2001-06-26 | 2007-04-03 | Astrazeneca Ab | Vinyl phenyl derivatives as GLK activators |
US20060258728A1 (en) | 2001-08-09 | 2006-11-16 | Kousuke Tani | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
US20050080106A1 (en) | 2001-08-17 | 2005-04-14 | Astrazeneca Ab | Compounds effecting glucokinase |
GB2385328A (en) | 2001-12-19 | 2003-08-20 | Hoffmann La Roche | Crystals of glucokinase and methods of growing them |
EP1336607A1 (en) | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
EP1496052A1 (en) | 2002-03-26 | 2005-01-12 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
US20060004010A1 (en) | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
US7230108B2 (en) | 2002-11-19 | 2007-06-12 | Astrazeneca Ab | Quinoline derivatives as glucokinase ligands |
EP1600442A1 (en) | 2003-02-26 | 2005-11-30 | Banyu Pharmaceutical Co., Ltd. | Heteroarylcarbamoylbenzene derivative |
US20060167053A1 (en) | 2003-02-26 | 2006-07-27 | Tomoharu Iino | Heteroarylcarbamoylbenzene derivative |
US20070078168A1 (en) | 2003-10-31 | 2007-04-05 | Caulkett Peter W R | Pyridine carboxylic acid derivatives as glucokinase modulators |
US20050165074A1 (en) | 2003-11-13 | 2005-07-28 | Ambit Biosciences Corporation | Amide derivatives as C-KIT modulators |
US20050261315A1 (en) | 2003-11-13 | 2005-11-24 | Ambit Biosciences Corporation | Amide derivatives as kinase modulators |
US20050171171A1 (en) | 2003-11-13 | 2005-08-04 | Ambit Biosciences Corporation | Amide derivatives as FLT-3 modulators |
US20050171172A1 (en) | 2003-11-13 | 2005-08-04 | Ambit Biosciences Corporation | Amide derivatives as PDGFR modulators |
US20050148605A1 (en) | 2003-11-13 | 2005-07-07 | Ambit Biosciences Corporation | Amide derivatives as ABL modulators |
EP1702919A1 (en) | 2003-12-29 | 2006-09-20 | Banyu Pharmaceutical Co., Ltd. | Novel 2-heteroaryl-substituted benzimidazole derivative |
CA2605738A1 (en) | 2005-04-25 | 2006-11-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Novel azaheterocyclic compounds as kinase inhibitors |
Non-Patent Citations (148)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100093757A1 (en) * | 2008-08-04 | 2010-04-15 | Astrazeneca Ab | Therapeutic agents 414 |
US8143263B2 (en) | 2008-08-04 | 2012-03-27 | Astrazeneca Ab | Therapeutic agents |
US20100210621A1 (en) * | 2009-02-13 | 2010-08-19 | Astrazeneca Ab | Crystalline polymorphic form 631 |
US8093252B2 (en) | 2009-02-13 | 2012-01-10 | Astrazeneca Ab | Crystalline polymorphic form of glucokinase activator |
Also Published As
Publication number | Publication date |
---|---|
KR20090068289A (ko) | 2009-06-25 |
UY30660A1 (es) | 2008-05-31 |
WO2008050101A3 (en) | 2008-07-17 |
AR063499A1 (es) | 2009-01-28 |
JP2010507640A (ja) | 2010-03-11 |
TW200825063A (en) | 2008-06-16 |
CA2667435A1 (en) | 2008-05-02 |
IL198142A0 (en) | 2009-12-24 |
CO6160318A2 (es) | 2010-05-20 |
PE20081467A1 (es) | 2008-12-07 |
BRPI0718504A2 (pt) | 2013-12-03 |
EP2086964A2 (en) | 2009-08-12 |
RU2009114982A (ru) | 2010-11-27 |
CL2007003033A1 (es) | 2008-05-16 |
WO2008050101A2 (en) | 2008-05-02 |
AU2007310608A1 (en) | 2008-05-02 |
NO20091599L (no) | 2009-07-21 |
US20080171734A1 (en) | 2008-07-17 |
MX2009004362A (es) | 2009-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7902200B2 (en) | Chemical compounds | |
US7943607B2 (en) | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | |
US7745475B2 (en) | Heteroaryl benzamide derivatives as GLK activators | |
US7642259B2 (en) | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | |
US7964725B2 (en) | Heteroarylbenzamide derivatives for use in the treatment of diabetes | |
EP1718624B1 (en) | Benzamide derivatives and their use as glucokinase activating agents | |
US20080234273A1 (en) | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | |
US20080312207A1 (en) | Compounds | |
US20110053910A1 (en) | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes | |
US20080280874A1 (en) | Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity | |
US20070287693A1 (en) | Benzamide Derivatives That Act Upon The Glucokinase Enzyme | |
US20100160286A1 (en) | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ASTRAZENECA AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAMPBELL, LEONIE;PIKE, KURT GORDON;SULEMAN, ABID;AND OTHERS;REEL/FRAME:020664/0302;SIGNING DATES FROM 20070810 TO 20071010 Owner name: ASTRAZENECA AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAMPBELL, LEONIE;PIKE, KURT GORDON;SULEMAN, ABID;AND OTHERS;SIGNING DATES FROM 20070810 TO 20071010;REEL/FRAME:020664/0302 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20150308 |